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Objectives: 
Phenotypic and molecular characterization of the carbapenemase producing Klebsiella 
pneumoniae and Escherichia coli causing blood stream infections by 
a. Phenotypic differentiation of carbapenemase and non-carbapenemase mediated 
mechanisms by the CarbaNP test. 
b. Molecular characterization ofthe isolates for blaNDM, blaKPC, blaOXA48 like, blaIMP, blaVIM 
genesby multiplex-PCR. 
c. To sequence a proportion of the positive isolates to determine the enzyme variants. 
 
Methods: 
During the study period 122 consecutive non- duplicate carbapenem resistant 
Klebsiella pneumoniae and Escherichia coli isolates causing blood stream infection 
were included in the study. The isolates were identified by cultural and biochemical 
characteristics. Carbapenemresistance was tested by imipenem and meropenem disk 
diffusion testing. CarbaNP test was done for the detection of carbapenemase 
production.Molecular characterization of the carbapenem resistant isolates was 
performed using amultiplex-PCR forblaNDM, blaKPC, blaOXA48 like, blaIMPand blaVIM 
genes. 20 random isolates positiveforblaOXA48 like and 7 isolates positive forblaNDM 
genes were sequenced to identify the enzyme variants. 
 
Results: 
Of the 122 isolates 97% were positive for carbapenemase production by CarbaNP test. 
blaNDM was found to be the predominant gene seen in 40% of the isolates. This was 
followed by blaOXA48like gene in 39%. 12% of the strains showed co-existence of both 
blaNDM andblaOXA48likegenes.None of the isolates showed blaVIM, blaKPCand 
blaIMPgenes.All the 20 (100%) of the blaOXA48 like genes were found to be blaOXA181 a 
variant of the blaOXA48 like gene. The 7 blaNDM gene positives were found to be 
theblaNDM 1 variant. 
 
Key words: Klebsiella pneumoniae, Escherichia coli, Carbapenem, resistance, India 
 
12 
 
1. Introduction 
 
The family Enterobacteriaceae encompassesgram negative bacilli which are 
resident flora of the human intestine and are among the most common human 
pathogens. They  cause infections such as pneumonia,septicaemia, peritonitis, 
cystitis,meningitis, pyelonephritis with fever, nosocomial and device-related 
infections(1).  
Gram negative enteric bacilli are a prominent cause for sepsis in children and 
adults.The infections caused by Enterobacteriaceae are community- and hospital-
acquired as these bacteria have the potential to spread in the hospital environment 
and also across continents(2)(3). Irrational use of antibiotics coupled with rapid 
emergence of drug resistance in bacteria is a major problem faced by health care 
setting around the world.  The production of β-lactamase is the most common 
mechanism of resistance to drugs especially in gram negative bacteria(4). 
Carbapenems are broad spectrum antibiotics belong to the β-lactam group.These 
drugs were primarily introduced in the 1980s for the treatment of ESBL producing 
gram-negative bacilli.  Like other β-lactam antibiotics they act by inhibiting the 
cell wall synthesis and display a time dependent bactericidal activity. 
Carbapenems are highly active against most of the aerobic and anaerobic bacteria 
except Entercoccus spp, MRSA(Methicillin resistant Staphylococcus aureus), 
Stenotrophomonas maltophilia and members of the genera; Rickettsia, Chlamydia 
and Mycoplasma(5). 
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1.1 Carbapenemase producing gram negative bacilli 
Carbapenemases are a versatile group of β-lactamases that are characterised by 
their resistance to virtually all β-lactam antibiotics, including the cephalosporins 
and carbapenems. They have also been found to be resistant to other classes of 
drugs like fluoroquinolones, aminoglycosides and co-trimoxazole.  
The carbapenemases fall into three classes according to their amino acid 
sequence.  (Table 1.1) 
Table 1.1 Classification of carbapenemase enzyme based on amino acid 
sequences 
Class of carbapenemases Representative enzymes 
Ambler Class A 
KPC, SME, NMC-A, IMI, PER, GES, 
SFC,  
Ambler Class B 
(Metallo β- lactamase) 
VIM, GIM, SIM, NDM, IMP, SPM 
 
Ambler Class D 
(Oxacillinases) 
OXA, PSE 
 
Abbreviations in table 1.1: 
KPC - Klebsiella pneumoniae carbapenemase 
SME - Serratia marcescens enzyme 
NMC - Non metallo-enzyme carbapenemase 
IMI - Imipenem-hydrolyzing β-lactamase 
PER - Pseudomonas extended resistant 
GES - Guiana extended spectrum 
SFC – Serratia  
VIM - Verona integron-encoded MBL 
GIM - German Imipenemase 
SIM - Seoul imipenemase 
NDM - New Delhi MBL 
IMP - Active on imipenem 
SPM - Sao Paulo MBL 
OXA – Oxacillinase 
PSE –Pseudomonas specific enzyme 
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The resistance to carbapenem groups of drugs is on the rise. It is especially of 
concern in the nosocomial pathogens which are multidrug resistant. The most 
common mechanism of carbapenem resistance in Enterobacteriaceaeis the 
production of carbapenemase enzymes. These enzymes are carried on mobile 
plasmids and have a greater propensity to cause outbreaks (6). The prevalence of 
carbapenem resistant Enterobacteriaceae in India has been reported to vary from 
5.3% to as high as 51% (7–9) 
Carbapenemases belonging to class A of molecular classification include KPC (K. 
pneumoniae carbapenemase), GES (Guiana extended-spectrum β- lactamases, 
Nmc-A (non- metallo-carbapenemase-A)/ IMI (imipenem-resistant), SME 
(Serratia marcescens enzyme), SFC (serratia fonticola carbapenemase), and BIC 
β--lactamases. 
Plasmid mediated, Ambler class B, carbapenemases which were widely found in 
Pseudomonas and other non-fermenting gram negative bacilli are now being 
increasingly identified in Enterobacteriaceae.  Metallo β- lactamases (Mβ-L) are 
named so because their activation requires binding of metal ions such as divalent 
zinc ion to specific site.  Various families of Mβ-Ls are identified in different 
parts of the world namely Imipenemase (IMP), Verona Integron encoded Mβ-L 
(VIM), Sao Paulo Mβ-L (SPM), German Imipenemase (GIM) and Seoul 
Imipenemase (SIM). Of these, members of VIM and IMP family have a 
worldwide distribution. Recent identification of New Delhi metallo-β-lactamase-1 
(NDM-1) producers, originally in the United Kingdom, India, and Pakistan and 
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now worldwide, is worrisome. NDM is now the most commonly isolated enzyme 
from the Indian subcontinent and is rapidly spreading worldwide (10).  
Carbapenemases of the oxacillinase-48 type have been identified mostly in 
Mediterranean and European countries and in India. This group ofβ- lactamases is 
capable of hydrolysing penicillins, cloxacillin, oxacillin and are poorly inhibited 
by clavulanic acid and EDTA. Their prevalence is on a rise and have in recent 
studies found to be the predominant carbapenemases in countries like France and 
Belgium(11,12).  
Identification of the carbapenem resistancein vitro relies on phenotypic methods 
and molecular techniques.The phenotypic tests can be used for screening of 
clinical isolates for the presence of carbapenem resistance, but the genotypic 
methods such as PCR are the confirmatory tests (13).  
 
1.2 Need for surveillance of antibiotic resistance  
The emergence of drug-resistant organisms both in the hospital environment and 
in the community is a major concern for health care providers. Surveillance 
studies have provided important information about changes in the spectrum of 
microbial pathogens and trends in the antimicrobial resistance patterns in both 
nosocomial and community-acquired infections. Continued monitoring of 
antimicrobial resistance patterns in hospitals is essential to guide effective 
empirical therapy. 
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Adequate detection of multidrug resistant microorganisms in the routine 
diagnostic laboratory is essential for patient care because  
(i) it is essential for the appropriate choice of antibiotic   
(ii)  it guides institution of suitable hospital infection control measures as these 
microorganisms are associated with rapid spread/outbreaks that result in 
increased morbidity, mortality, prolonged hospital stay and increased 
treatment costs. 
 
The present study is a descriptive study done with this background in a tertiary care 
centre. We intended to characterize the mechanisms of carbapenem resistance in 
Klebsiella pneumoniae and Escherichia coliand to study the susceptibility profile of 
these organisms to other classes of drugs.  
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2.  Aim of the study 
 
To characterize the different carbapenem resistance mechanisms in Klebsiella 
pneumoniaeand Escherichia coliisolated from blood stream infections using 
phenotypic and genotypic methods. 
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3. Objectives 
 
i. To identify the carbapenem resistant isolates by disk diffusion for imipenem 
and meropenem. 
ii. To compare the antimicrobial susceptibility pattern of these isolates for first 
line antimicrobial agents and to determine the susceptibility of these isolates to 
second line antimicrobials using the disk diffusion technique. 
iii. To detect the various carbapenem resistance mechanisms by performing the 
following tests: 
a. Phenotypic differentiation of carbapenemase and non-carbapenemase mediated 
mechanisms by the CarbaNP test. 
b. Molecular characterization of the isolates forblaNDM, blaKPC, blaOXA48 like, blaIMP, 
blaVIM genesby multiplex-PCR. 
c. To sequence a proportion of the positive isolates to determine the enzyme 
variants. 
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4. Review of literature 
 
4.1 Enterobacteriaceae and blood stream infections 
Enterobacteriaceae are one of the most important family of bacteria that comprises of 
rod shaped, gram negative bacteria which are inhabitant flora of the human intestine 
and are among the most common human pathogens.  They cause infections such as 
septicaemia, pneumonia, peritonitis, meningitis, cystitis and pyelonephritis with fever, 
and device-associated infections both in adults and children. They account for about 
50% cases of blood stream infections(14).Escherichia coli(E. coli), Klebsiella 
pneumoniae(K. pneumoniae) and Enterobacter spp. are the most frequent members of 
the family causing a variety of community and nosocomial infections such as urinary 
tract infections, lower respiratory tract infections, post-surgical intra-abdominal 
infections and bacteraemia(15). 
Blood stream infections have a varied presentation from self-limiting infections to life 
threatening sepsis and necessitate prompt and aggressive therapy. The aetiology of 
blood stream infections includes a wide spectrum of organisms and varies among 
different geographical regions(16).The bacterial causes of blood stream infections 
includes gram positive organisms such as Staphylococcus aureus, coagulase negative 
Staphylococcus spp, and Enterococcus species; gram negative bacteria such as E.  
coli, K. pneumoniae among Enterobacteriaceae; and  non-fermenting gram negative 
bacilli Pseudomonas spp and Acinetobacter baumannii.  Blood stream infections can 
be community acquired or hospital acquired(17).  Gram negative bacilli are becoming 
an important cause of blood streaminfections especially in the hospital acquired 
infections(18).  There are many reports of an etiological shift with predominance of 
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gram negative bacteraemia from various countries(19–22).  Increasing prevalence of 
gram negative bacteremia has also been reported in both adult and paediatric 
populations from India(23–25). The knowledge of common aetiology is essential for 
accurate and targeted empirical therapy in these patients. 
The increasing prevalence of multidrug resistance in gram negative bacilli complicates 
the treatment of blood stream infections caused by these pathogens. Bacteria that were 
earlier susceptible can becomeresistant by acquiring plasmids from other bacteria, by 
mutation or by selection of resistant mutants during the course of therapy. 
The widespread dissemination of Extended spectrum β- lactamase and carbapenemase 
producing Enterobacteriaceae is becoming a major concern as the therapeutic options 
are limited and increasing treatment failure is noted(26). 
 
4.2 Pharmacology of carbapenems  
4.2.1 Carbapenems 
Carbapenems are broad spectrum antibiotics belonging to the large family of β- 
lactam antibiotics. Carbapenem antibiotics have a broad spectrum of activity against 
many gram positive and gram negative bacteria. The term carbapenem is defined as 
“the 4:5 fused ring lactam of penicillins with a double bond between C-2 and C-3 but 
with the substitution of carbon for sulphur at C-1”. The stereochemistry of the 
hydroxyl-ethyl side chain of the carbapenems is a major trait of carbapenems and is 
vital for their activity (fig.4.1).  Resembling the other β--lactam antibiotics penicillin 
and cephalosporins, carbapenems act by binding to the penicillin binding proteins 
PBPs and inhibiting cell wall synthesis in the bacteria.Among the β-lactams, 
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carbapenems were considered exceptional because they were relatively resistant to 
hydrolysis by most β-lactamases including extended-spectrum β-lactamases (ESBLs) 
and AmpCβ-lactamases. Thus when introduced on 1980‟s, carbapenems were used as 
antibiotics of choice in infection with drug resistant pathogens.(5) 
 
                                          Fig.4.1. Structure of carbapenems. 
                                                       Adapted from (5) 
 
4.2.2 Mechanism of action 
Carbapenems enter the bacterial cell wall through outer membrane proteins called 
porins as they cannot easily diffuse through the cell wall. After they enter the 
periplasmic space they permanently acylate the penicillin binding proteins (PBPs) 
such as PBP1a, 1b, 2 and 3. PBPs are enzymes that act as catalysts in the last step of 
trans-peptidation in synthesis of peptidoglycan resulting in the disruption of cell wall. 
β-lactams inhibit the crosslinking of peptidoglycan   causing a build-up of precursors, 
that activate the autolytic enzymes for digestion of existing peptidoglycan. 
Consequently, the structural integrity of the cell wall decreases and bacterial lysis 
occurs(26). 
The carbapenems available and under development are classified into 3 groups, their 
spectrum of activity issummarized in Table 4.1. 
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Table 4.1. Carbapenem antibiotics available and under development 
Carbapenems Group1 Group2 Group3 
 Ertapenem 
Panipenem 
Tebipenem 
 
Imipenem 
Meropenem 
Doripenem 
Biapenem 
Tomopenem 
Razupenem 
 
 
4.2.3 Pharmacology 
Carbapenems have similar pharmacokinetic profile but they differ in their half-lives. 
Imipenem is metabolized and thus inactivated by the dehydropeptidase-I (DHP-I) 
enzyme in the proximal tubules of the kidney. Clinically it is used in combination with 
a DHP-I inhibitor cilastatin in 1:1 ratio for attaining adequate concentrations in serum. 
Meropenem,ertapenem and biapenem do not require concomitant administration of 
DHP-I inhibitor. Doripenem, imipenem and meropenem have similar pharmacokinetic 
properties.(27) 
Meropenem and imipenem are renally excreted. Elimination of ertapenem is by 
acombined mechanismof conversion to a β-lactam ring-opened derivative by a 
hydrolytic metabolism andexcretionthrough kidney by glomerular filtration and 
secretion of the unchanged drug.  Doripenem is excreted unchanged in the urine by 
glomerular filtration and tubular secretion(16). 
Carbapenems are distributed primarily extracellularly and are also distributed in wide 
variety of tissues. The tissue concentration of these drugs is in the same range as that 
in the plasma(28). 
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Ertapenem is highly protein bound and an actual estimation of albumin is required for 
deciding the dosage interval of this drug. This also ensures optimal dosage in patients 
who are critically ill and may have hypoglobulinemia(29). 
4.2.4 Spectrum of activity 
Carbapenems exhibit a generally broader in vitro antimicrobial spectrum when 
compared to the other availableβ-lactams andβ-lactam/β-lactamase inhibitor 
combinations. Imipenem, doripenem and panipenem,are more potent antibiotic agents 
acting against Gram-positive organisms. Meropenem, ertapenem, biapenem and 
doripenem are slightly more effective against Gram-negative bacteria. Important 
aspects toconsider for carbapenem antibiotics are that ertapenem has a more limited 
activity when compared to imipenem or meropenem against non-fermenting gram 
negative bacilli such as P. aeruginosa.  Imipenem and doripenem are more potent for 
A. baumannii. Also,doripenem is the drug in this class that is least susceptible to 
hydrolysisby carbapenemase enzymes(30). 
Carbapenems when used in combination with other antimicrobialagents are used to 
treat serious infections. Combination therapy of carbapenem and other antimicrobials 
has become an important area of study as the MDR infections are on the rise and these 
pathogens requireaggressive and prompt initiation of therapy (5). The spectrum of 
activity of the carbapenems are summarized in table 4.2 
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Table 4.2 Spectrum of activity of the carbapenems 
Carbapenems Ertapenem 
Panipenem 
Tebipenem 
 
Imipenem 
Meropenem 
Doripenem 
Biapenem 
Tomopenem 
Razupenem 
Activity against 
gram negative 
bacilli 
Yes Yes Yes 
Activity against 
non- fermenting 
gram negative 
bacilli 
No Yes Yes 
Activity against 
MRSA 
No No Yes 
 
 
 
4.2.5 Safety profile 
β-lactam antibiotics are the most commonly prescribed class of antibiotics as they 
have a good safety profile when compared with other antibiotics.Anaphylaxis to β-
lactam compounds in patients with allergy to these drugs can also occur with 
carbapenems.Other commonlyencountered adverse effects include headache, mild 
hypotension, localized rash and phlebitis at the injection site.Carbapenems are 
otherwise generally well tolerated.(27) 
 
4.3 Mechanisms of carbapenem resistance in Enterobacteriaceae 
 
In Enterobacteriaceae, resistance to carbapenems can be due to the following 
mechanisms:  
A) Carbapenemase mediated mechanism: 
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(i) Acquiringgenes that encode for a β- lactamase enzymes capable of 
hydrolyzing carbapenems and most of the β-lactam agents. 
B) Non carbapenemase mediated mechanisms: 
(i) A decrease in the uptake of antibiotics bya reduction in expression of porin 
channels 
(ii) Over-expression of efflux pumps  
The porin proteins are trans-membrane ion channels which facilitate the entry of 
antimicrobials and other hydrophilic compounds, while efflux pumps are cell wall 
proteins which actively extrude the harmful substances entering into the bacterial 
cell(26). Contrary to carbapenemases, these mechanisms are physiological 
modifications and are not specific to β-lactam agents. 
 
4.3.1 Carbapenemase mediated mechanism 
 
In Enterobacteriaceae, the foremost mechanism involved in resistance toβ-lactams 
is the production of certain enzymes, termedβ-lactamases, that exhibit hydrolytic 
activity against β-lactam ring in the antibiotics. Depending on theiractivity for easy 
understanding these enzymes are grouped into four groups: 
i. Penicillinases: these enzymes inactivate penicillins but are unable to degrade 
otherβ-lactam antibiotics such as cephalosporins, aztreonam and carbapenems. 
ii. Cephalosporinases are enzymes that preferentially degrade cephalosporins and 
amino penicillins, but have no effect on other carboxy penicillins, ureido-
penicillins, aztreonam, and carbapenems. 
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iii. Extended-spectrum b-lactamases (ESBL) inactivate majority of β-lactam 
antibiotics except carbapenems.  
iv. Carbapenemases inactivate carbapenems and dependingon the enzyme, other 
types of β-lactam molecules as well.(26) 
 
4.3.1.1 Introduction 
 
Carbapenemases are a class of versatile β-lactamases, which have hydrolytic 
activity against the carbapenems and most of the other β-lactam antibiotics. They 
are also most resistant to hydrolysis by β lactamase inhibitors.By 1990‟s most 
classes of carbapenemases had been discovered and were thought to be specific 
for the species in which they were identified and chromosomally mediated. But 
the discovery of similar genes in other species of bacteria led to need for 
classification and study of these enzymes (6).   
 
4.3.1.2 Classification schemes 
The classification of β-lactamase enzymes are based on either functional 
characteristics or thestructure of the enzymes. The Amblerclassification is based 
on the structure i.e.protein sequence. In this classification on the basis of amino 
acid homology the enzymes are classified into four classes A, B, C, and D. 
Classes A, C,and D include enzymes that have serine at its active site and 
hydrolyze their substratesby formingan acyl enzyme. ClassB β-lactamases utilize 
at least one zinc ion at the active site to hydrolyse β-lactams and hence named 
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metallo-enzymes. The structural classification was simple and less controversial 
but lacked the details of the enzymatic activity of the enzymes such as hydrolytic 
and inhibition properties(31). The functional classification was first proposed by 
Bush in 1988 and many additions and modifications were made as the new 
enzymes with their differing functional profile were discovered. 
 
Table 4.3. Classifiction of β- lactamase enzymes 
Bush-
Jacoby 
group 
(2009) 
Molecular 
class 
(subclass) 
Substrate(s) Attributes Representative 
enzymes 
1 C Cephalosporins Greater hydrolysis 
of cephalosporins 
than 
benzylpenicillin; 
hydrolysis of 
cephamycins 
ACT-1, CMY-
2, 
FOX-1, MIR-1 
1e C Cephalosporins Increased 
hydrolysis of 
ceftazidime 
and often other 
oxyimino-β- 
lactams 
CMY-37 
2a A Penicillins Greater hydrolysis 
of 
benzylpenicillin 
than 
cephalosporins 
Staphylococcal 
penicillinases 
2b A Penicillins, 
early 
cephalosporins 
Similar hydrolysis 
of benzylpenicillin 
and cephalosporins 
TEM-1,2 ,SHV-
1 
2be A Extended-
spectrum 
cephalosporins, 
monobactams 
Increased 
hydrolysis of 
oxyimino- β- 
lactams 
(cefotaxime, 
ceftazidime, 
ceftriaxone, 
TEM-3, SHV-2, 
CTX-M-15, 
PER-1, VEB-1 
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cefepime, 
aztreonam) 
 
2br A Penicillins Resistance to 
clavulanic acid, 
sulbactam, and 
tazobactam 
 
TEM-30, SHV-
10 
2ber A Extended-
spectrum 
cephalosporins, 
monobactams 
Increased 
hydrolysis of 
oxyimino- β- 
lactams combined 
with resistance 
to clavulanic acid, 
sulbactam, and 
tazobactam 
 
TEM-50 
2c A Carbenicillin Increased 
hydrolysis of 
carbenicillin  
PSE-1 
2ce A Carbenicillin, 
cefepime 
Increased 
hydrolysis of 
carbenicillin, 
cefepime, and 
cefpirome 
RTG-4 
2d D Cloxacillin  Increased 
hydrolysis of 
cloxacillin or 
oxacillin 
 
OXA-1, OXA-
10 
2de D Extended-
spectrum 
cephalosporins  
 
 
Hydrolyzes 
cloxacillin or 
oxacillin 
and oxyimino- β-
lactams 
OXA-11, OXA-
15 
2df D Carbapenems  Hydrolyzes 
cloxacillin or 
oxacillin 
and carbapenems 
 
OXA-23, OXA-
48 
2e A Extended-
spectrum 
cephalosporins 
 
 
Hydrolyzes 
cephalosporins. 
Inhibited by 
clavulanic acid but 
not aztreonam 
CepA 
2f A Carbapenems  Increased KPC-2, IMI-1, 
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hydrolysis 
ofcarbapenems, 
oxyimino-β-
lactams, 
cephamycins 
 
SME-1 
3a B Carbapenems 
 
Broad-spectrum 
hydrolysis 
including 
carbapenems but 
not 
monobactams 
 
IMP-1, VIM-1 
3b B Carbapenems  Preferential 
hydrolysis of 
carbapenems 
 
CphA, Sfh-1 
 
 
4.3.1.3Molecular Class-A β- lactamases 
Carbapenemases belonging to class A of molecular classification and group 2f of the 
functional classification were discovered over 20 years ago and now have been 
sporadically isolated from various clinical samples. These β--lactamases have been 
found in various genera such asSerratia spp,Enterobacter sppand Klebsiella spp. The 
enzymes that fall in this group are KPC (K. pneumoniae carbapenemase), GES 
(Guiana extended-spectrum β- lactamases, Nmc-A (non- metallo-carbapenemase-A)/ 
IMI (imipenem-resistant), SME (Serratia marcescens enzyme), SFC (serratia 
fonticola carbapenemase), and BIC β--lactamases (21).They occur as sporadic isolates 
or as outbreaks in hospitals. The chromosomally encoded enzymes of this class are 
SME, NMC, and IMI. The antibiotic profile of bacteria expressing these chromosomal 
β-lactamases belonging to group 2f is distinct. They exhibit resistance to carbapenems 
and susceptibility to extended spectrum cephalosporins.These enzymes confer the 
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bacteria carrying them with reduced susceptibility to imipenem, the MICs(minimum 
inhibitory concentration) for these enzymes can have a variable range from mildly 
high to completely resistant. These β-lactamases, therefore, may be difficult to 
recognize on routine susceptibility testing by disk diffusion methods (6).  KPC and 
GES are the plasmid encoded enzymes in this group. Two features that separate the 
KPC carbapenemases from the other carbapenemases in the functional group 2f. First, 
that these enzymes are found on plasmids that are transferrable and 
secondlythathydrolyse cephalosporins such as cefotaxime which are classified as 
amino-thiazoleoxime cephalosporins. The KPC β-lactamases have largely reported 
from Klebsiella spp.they have also been reported from Enterobacter spp. and 
Salmonellaspp. 
The KPC family has the highest potential for spread among the group 2f enzymes 
because of its location on plasmids, found in Klebsiella spp which are bacteria known 
for their ability transfer resistance plasmids to other bacteria(6) 
The GES is a not so frequently found family of carbapenemases. It was first identified 
from E. cloacae in Greece. They have been reported from other parts of the world 
subsequently. They have a wide spectrum of hydrolytic activity  similar to ESBL‟s 
from extended spectrum penicillins to carbapenems sparing the monobactums.(6) 
KPC is the most commonly isolated clinically all the other enzymes of this class are 
rare.(32) 
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4.3.1.4 Class B metallo- β—lactamases 
Metallo β--lactamases are characterized by  their distinct functional properties:  ability 
to hydrolyze carbapenems, resistance to β- lactamase inhibitors, susceptibility to 
inhibition by ion chelators such as EDTA(33).  Their spectrum of substrates 
hydrolysed include carbapenems, cephalosporins and penicillins. These enzymes lack 
hydrolytic activity against aztreonam. The mechanism of action is based on interaction 
of the β- lactam ring with the zinc present at their active site. The zinc ions present at 
their active site are vital for the nucleophilic hydrolysis of the β--lactam ring.  This 
property makes them susceptible to metal ion chelators such as EDTA(6). Three 
lineages of the metallo β- lactamases have been suggested based on phylogenetic 
analysis B1,B2 and B3 (34). This classification scheme is based on the on the 
placement of the zinc organising residues and comprises of both chromosomal and 
plasmid encoded enzymes. The subgroup B1 includes chromosomally encoded β- 
lactamases enzymes and plasmid borne acquired enzymes like IMP,VIM,NDM,SPM. 
These variants have been found in K. pneumoniae and other genera in the family 
Enterobacteriaceae.  They are grouped together as they possess the zinc coordinating 
residues histidine and cysteine.  Class B2 comprises of those enzymes which contain 
asparagine instead of histidine at the zinc binding motif and are derived from Serratia 
fonticola and Aeromonas spp. Class B3 has only one enzyme L1 which is represented 
as a tetramer in contrast to the other enzymes (35).  IMP-1 was the first among these 
carbapenemase to be identified from Japan in 1991from Serratia marcescens and was 
recognized as a source of resistance which is acquired. VIM-1 was described in 1997 
froman isolate of P. aeruginosaVerona in Italy.IMP amd VIM share less than 30% 
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identity in the amino acids they have similar spectrum profiles. IMP and VIM 
producing K. pneumoniae have been found to have MIC for carbapenemases ranging 
from 4 to 32 µg/ml. The variability in the MIC‟s may pose a challenge in their 
identification in the laboratory (36). NDM enzyme was identified in 2008 and were 
the latest enzymes to be discovered.  These enzymes have now been reported from 
different countries worldwide.  They are known to cause hospital acquired and 
community acquired infections, and also in urban contaminated water from the Indian 
subcontinent. The predominant type is NDM-1, but many minor variants have been 
isolated. NDM enzymes are present principally in Enterobacteriaceae, in non-
fermenting gram negative bacilli and familyVibrionaceae. The blaNDM-1 genetransfer 
has resulted in the widespread dissemination of the gene.The NDM carrying bacteria 
are usually resistant to almost all antibiotics, and their detection and surveillance are 
vital.(37) 
 
4.3.1.5 Class D serine-carbapenemases: the OXA β—lactamases 
 
 
In the 1970‟s and early 1980‟s Oxacillin-hydrolyzing (OXA) β-lactamase enzymes 
were the most prevalent enzymes of the plasmid encoded enzyme families. They were 
initially identified in the non-fermenters and later in the family Enterobacteriaceaeand 
were placed in a different class from the other serine β-lactamases. They were β- 
lactamases capable of hydrolysing penicillins, cloxacillin, oxacillin and were poorly 
inhibited by clavulanic acid and EDTA(6).  Hence they were given the name 
oxacillinases and the prefix OXA. They were placed in the group 2d of the Bush-
Jacoby functional classification. The class D β- lactamases have been idientified 
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mainly as plasmid encoded enzymes in contrast to class A and C. The early 
oxacillinases were penicillinases until an ESBL oxacillinase OXA-11 was isolated 
from P. aeruginosa, as a result of mutation.  Several ESBL OXA enzymes were 
described following this. The OXA -23 was the first carbapenem resistant oxacillinase 
described which had high imipenem MIC (38). Many subgroups of the OXA 
carbapenemases have been described based on the amino acid homologies as abridged 
in table 4.4. 
The OXA-23-like, OXA-40-like, OXA-51-like, OXA-58-like, OXA-134a- like, OXA-
143-like, OXA-213, OXA-214-like, OXA-211-like, OXA-229-like, OXA-235-like 
carbapenemase have been identified and are restricted to Acinetobacter spp where as a 
novel oxacillinase hydrolysing carbapenems was isolated from a Klebsiella 
pneumoniae isolate from Istanbul in Turkey. This enzyme variant was named OXA-
48. The OXA-48 and its variants have now been isolated from different parts of the 
world in Enterobacteriacae and also A. baumannii (38).  The enzyme kinetics of the 
OXA-48 enzyme demonstrated that they have low hydrolytic activity against 
carbapenems, with more potent activity against imipenem than against meropenem. 
They are not inhibited by β- lactamase inhibitors like clavulanic acid, tazobactum and 
sulbactam (39).  10 more OXA-48 variants have been recognised which include OXA-
162, OXA-163, OXA-181, and OXA-232. OXA-163 has a poor hydrolytic activity 
against carbapenems but has ability to hydrolyze aztreonam and ceftazidime, which is 
not observed with OXA-48. The OXA-181 and OXA-232 enzymes seem to be 
approximately like OXA-48 in their activity (38).  
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Table4.4 Carbapenemase OXAβ- lactamases and their variants 
Group of OXA 
carbapenemases 
Enzymes in the group 
OXA-23-like OXA-23, OXA-27, OXA-49, OXA-73, OXA-102, 
OXA-103, 
OXA-105, OXA-133, OXA-134, OXA-146, 
OXA-165–OXA-171, OXA-225, OXA-239 
OXA-40-like  
 
OXA-40, OXA-25, OXA-26, OXA-72, OXA-139, 
OXA-160, 
OXA-207 
OXA-51-like  
 
OXA-51, OXA-64–OXA-71, OXA-75–OXA-80, OXA-
82– 
OXA-84, OXA-86,OXA-95, OXA-98–OXA-100, OXA- 
104, OXA-106–OXA-113, OXA-115–OXA-117, OXA- 
120–OXA-128, OXA-130–OXA-132, OXA-138, OXA- 
144, OXA-148–OXA-150, OXA-172–OXA-180, OXA- 
194–OXA-197, OXA-200–OXA-203, OXA-206, OXA- 
208, OXA-216, OXA-217, OXA-219, OXA-223, OXA- 
241, OXA-242, OXA-248–OXA-250, OXA-254 
OXA-58-like OXA-58, OXA-96, OXA-97, OXA-164 
OXA-134a- like OXA-134a, OXA-186–OXA-191 
OXA-143-like  OXA-143, OXA-182, OXA-231, OXA-253, OXA-255 
OXA-213  OXA-213 
OXA-214-like  OXA-214, OXA-215 
OXA-211-like  OXA-211, OXA-212, OXA-309 
OXA-229-like  OXA-228,OXA-230, OXA-257 
OXA-235-like  OXA-235,OXA-237, OXA-278 
OXA-48-like  
 
OXA-48, OXA-48b, OXA-162, OXA-163, OXA-181, 
OXA-199, OXA-204, OXA-232, OXA-244, OXA-245, 
OXA-247 
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4.3.2 Non carbapenemase mediated mechanisms 
4.3.2.1 Loss of porin channels 
The Gram-negative bacteria are protected from external toxic agents such as heavy 
metals and detergents by the outer membrane which is hydrophobic in nature.  The 
outer membrane contains certain trans- membrane proteins, called porins. Porins act 
as hydrophilic channels for the entry of vitalnutrients and other compounds, as well as 
antibiotics. (40). The passage of molecules through porins is size dependent; smaller 
molecules pass through easily than the larger ones(41). The porin channels are of 
various types out of which the outer membrane porins (Omp) are significant in 
Enterobacteriaceae.  The porin channels involved in the uptake of antibiotics in 
Enterobacteriaceae belong to the family OmpF or OmpC. (42) 
 
A number of studies have reported an association between modifications in the porin 
channel type in antibiotic-resistant bacterialisolates. Enterobacteriaceae can show 
analteration in the type of porin channels they express, low level of porin expression 
orthe existence of a mutated porin channel. (42,43)β-lactam antibiotics are the most 
commonly affected class of antibiotics by porin changes as porin channel  are a part of 
the entry pathway of these drugs . Therefore, any alterations in the number oractivity 
of porin channelscan have an influence on antibioticresistance.  
In Klebsiella pneumoniae, OmpK35 and OmpK36 are the major non-specific porins 
and in Escherichia coli OmpC, OmpF are the identified porins which help in the 
transportation of carbapenems into the bacterial cell. (44,45) 
Resistance mediated by porin loss is related to the molecular size of the carbapenem. 
These strains develop high level resistance to the larger molecule ertapenem which 
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depend on porins for its entry. On the contrary, low level resistance or reduced 
susceptibility is observed with the smaller imipenem and meropenem(27)(23). 
Presence of ESBL and Amp C enzymes along with defects in outer membrane 
permeability can be responsible for carbapenem resistance in gram negative 
bacilli(26). 
 
4.3.2.2 Efflux pumps 
Efflux pumps are complex proteins present in the bacterial cell envelope which 
actively pump out substances from the cell to the exterior. These pumps play a dual 
role in the bacterial physiology by excreting the poorly diffusible metabolites 
produced endogenously and by extruding out the harmful exogenous substances which 
diffuse in from the environment(47)(48). Hence administration of antibiotics have 
probably exerted a selective pressure for over expression of efflux pumps resulting in 
a non-specific mechanism of resistance(49). 
Efflux pumps function either by primary or secondary active transport. The former 
acquires energy from ATP hydrolysis while the latter is driven by ion gradients. There 
are many families of efflux pumps with numerous members under each family, of 
which the members of the Resistance Nodulation Division (RND) super family 
contribute to antimicrobial resistance. All the pumps of the RND super family are 
secondary active transporters and are exclusively found in gram-negative bacteria. 
The notable member responsible for efflux of β--lactams in the Enterobacteriaceae is 
the AcrAB–TolC pump(50). Usually, strains resistant to carbapenems due to hyper-
functioning efflux pumps also produce ESBLs(51). 
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Numerous natural and synthetic molecules have been tested for inhibition of efflux 
pumps so that they may be used in vivo for therapy but due to concerns about their 
efficacy and safety, none has been approved yet(42,50,52). Two compounds namely 
carbonylcyanide m-chlorophenylhydrazone (CCCP) and phenylalanine arginine β- 
naphthylamide (PABN) are currently used for the in vitro detection of bacterial efflux 
pumps. Both these chemicals are broad spectrum efflux pump inhibitors (EPI) with 
different mechanisms of action. CCCP inhibits efflux pump activity by abolishing the 
ion gradient while PABN acts as a competitive inhibitor(53). 
Apart from carbapenem resistance, efflux pumps also contribute to resistance to 
fluoroquinolones and other antimicrobials, antiseptics and detergents (50,54). Efflux 
pumps have also been implicated in the increased resistance of biofilms to 
antimicrobials (44) .It is also presumed that the AcrAB efflux pump is a virulence 
factor which enables Klebsiella pneumoniae to resist the innate defences of the lung 
and facilitate the onset of pneumonia(55). 
 
4.4 Methods of detection of carbapenemases in Enterobacteriaecae 
 
The detection of mechanism of resistance to carbapenems is of value in infection 
control and public health practices and epidemiological investigations. There are 
various techniques available for detection of carbapenemase production by 
Enterobacteriacae.  They can be broadly classified into phenotypic tests and 
genotypic tests. Most phenotypic tests use the principle of inhibition by specific 
inhibitors, where the susceptibility to a carbapenemantibiotic is regained when tested 
along with inhibitors specific for each Ambler class of carbapenemase. Whereas the 
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genotypic tests directly detect the genes encoding for a specific type of carbapenemase 
enzyme. 
 
4.4.1 Phenotypic methods 
4.4.1.1 Disk diffusion testing with carbapenems 
CLSI(The Clinical and Laboratory Standards Institute) and EUCAST (European 
Committee on Antimicrobial Susceptibility Testing) recommend disk diffusion testing 
of the clinical isolateswith carbapenems such as meropenem, ertapenem, imipenem 
and doripenem as a screening test forcarbapenem resistance. Ertapenem disk diffusion 
is the most sensitive method but has less specificity. Meropenem disk diffusion has 
been found to have the best balance between sensitivity and specificity.  
The breakpoints for carbapenem antibiotics for Enterobacteriaceae have been optimized to 
detect all clinically important resistance mechanisms of resistance, including the majority of 
the carbapenemases. (56) 
 
Table 4.5 CLSI and EUCAST 2014 Breakpoints for disk diffusion testing 
Carbapenem Disk 
strength 
 
CLSI zone diameter interpretative 
criteria (mm) 
EUCAST zone 
diameter 
interpretative criteria 
(mm) 
Susceptible Intermediate Resistant Susceptible Resistant 
Doripenem 10µg ≥23 20-22 ≤19 ≥24 <21 
Ertapenem 10µg ≥22 19-21 ≤18 ≥25 <22 
Imipenem 10µg ≥23 20-22 ≤19 ≥22 <16 
Meropenem 10µg ≥23 20-22 ≤19 ≥22 <16 
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4.4.1.2 Minimum inhibitory concentration for carbapenems 
The minimum inhibitory concentration (MIC) of the isolates can be determined by 
macrobroth, microbroth dilution techniques or E-test method and can be interpreted 
using the standard guidelines as screening test to detect carbapenem resistance. 
Table 4.6CLSI and EUCAST 2014 Breakpoints for MIC testing 
Carbapenem CLSI MIC interpretative criteria 
(µg/ml) 
EUCAST MIC 
interpretative criteria 
(mg/L) 
Susceptible Intermediate Resistant Susceptible Resistant 
Doripenem ≤1 2 ≥4 ≤1 >2 
Ertapenem ≤0.5 1 ≥4 ≤0.5 >1 
Imipenem ≤1 2 ≥4 ≤2 >8 
Meropenem ≤1 2 ≥4 ≤2 >8 
 
In addition to manual methods mentioned above, many automated instruments are 
available which are capable of determining and interpreting the MIC of the test 
organism to a panel of antimicrobials. The noteworthy automated systems include 
Phoenix (Becton Dickinson) Vitek 2 (bioMérieux) and MicroScan (Siemens). Recent 
studies have shown manual methods to be more accurate than automated methods.(57) 
4.4.1.3 Phenotypic confirmatory test- Modified hodge test 
 
Modified hodge test (MHT) is recommended as a phenotypic confirmatory test by 
CLSI to detect the production of carbapenemase enzymes produced by the isolates. 
Carbapenemase production is detected by the MHT when the test isolate produces the 
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enzyme and allows growth of a carbapenem susceptible strain (E.coli ATCC 25922) 
towards a carbapenem disk. The result is a characteristic cloverleaf-like indentation. A 
positive MHT indicates that this isolate is producing a carbapenemase. A negative 
MHT indicates that this isolate is not producing a carbapenemase(58).  
The advantages of modified hodge test are that it is simple to perform, many isolates 
can be tested on the same plate and carbapenems of different classes can be detected 
by a single test (59). (fig.4.2) 
The limitations arethe class of carbapenemase cannot be determined by the results of 
the MHT, false positive results have been reported with AmpC β- lactamases. The 
modified hodge test has been observed to detect Class A and D carbapenemases, but 
has a lower sensitivity for NDM producing organisms(46, 47,48).  The results are also 
ready 24 hours after the isolate has been identified, thus it is considered time 
consuming.  
 
Fig.4.2 Modified hodge test for carbapenemase detection 
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4.4.1.4 Phenotypic detection using specific inhibitors 
Specific inhibitory substances can be used to differntiate between the different groups 
of carbapenemases. Phenyl boronic acid inhibits class A carbapenemases like KPC 
without inhibiting the growth of the organism. EDTA and dipicolinic acid inhibit the 
metallo β- lactamases. Dipicoloinic acid has been found to be more specific than 
EDTA when synergy with carbapenem are used for identification of Mβ-L. Currently 
no inhibitors are available for detection of OXA-48-like enzymes. High-level resistance to 
temocillin (MIC >32 mg/L) has been proposed as a phenotypic marker for OXA-48-like 
carbapenemase producers(60,61). As these markers are not specific for OXA carbapenemases 
genotypic confirmation is required. 
These substances are available commercially as disks of inhibitor-carbapenem 
combination or tablets and the E-test (Rosco NeoSensitabs
TM
 – 
Carbapenemases/Metallo-β--Lactamase Confirmative Identification pack).  Table 4.7 
summarizes the detection of β-lactamases using specific inhibitors. 
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Table 4.7 Mechanism of resistance to carbapenems using specific inhibitor 
substances 
 
Mechanism Synergy with meropenem disc                     Temocillin   
DPA/EDTA  APBA CLX    MIC 
>32µg/ml 
KPC - ≥ 4 - - 
MBL ≥ 5 - - - 
OXA-48 like - - - Yes 
AmpC+ porin 
loss 
- ≥ 4 ≥ 5 - 
ESBL+ porin 
loss 
- - - No 
 
Abbrevations used in the table 
APBA: aminophenylboronic acid, DPA:  dipicolinic acid, EDTA: 
ethylenediaminetetraacetic acid,  CLX= cloxacillin 
4.4.1.5CarbaNP test 
The CarbaNP test is a new phenotypic test for the detetction of carbapenemase 
production by Enterobacteriaecae and Pseudomonas spp. The principle of the test is 
in vitro hydrolysis of the imipenem ring by the carbapenemase produced by the 
bacteria to form an acidic compound which lowers the pH. The change in pH is 
detected by change of colour of the indicator phenol red from red to yellow. 
The bacterial isolate to be tested is incubated in a bacterial cell lysis solution.  
Following this the supernatant is mixed with imipenem, phenol red and zinc sulphate. 
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The bacteria producing carbapenemase will turn the colour of the solution from red to 
yellow. 
This test can be used for rapid screening (<2hrs)  of carbapenemase mediated 
resistance in Enterobacteriacae and Pseudomonas spp.  The sensitivity and specificity 
of this test were found to be 100% (62).  Tijet et al. in 2013 evaluated the test and 
found that the specificity was 100% but the sensitivity was 72.5% as compared to 
100% as published eariler. They also found the sensitivities to be lower for OXA 48 
like producers and isolates carrying GES-5 and SME-1 producers. In addition they 
had false negative results with mucoid strians (63).  
Table 4.8 summarizes the studies evaluationg CarbaNP test. 
Table 4.8 Sensitivity and specificity of the CarbaNP test 
Study  No. of 
isolates  
Compared 
with 
Sensitivity 
(%) 
Specificity 
(%) 
Reference 
Nordman 
P et al. 
162 - 100 100 (62) 
Vasoo et 
al. 
271 Modified 
hodge test  
100 100 (64) 
Knox et al. 105 PCR,MALDI 
TOF 
87 100 (65) 
Huang et 
al. 
356 Rosco Rapid 
CARB 
screen kit 
97 100 (66) 
Tijet et al. 244 Modified 
hodge test 
72.5 100 (63) 
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CarbNP is a rapid test, technically less demanding, inxepensive as compared to 
molecular test and also has a good sensitivity and specificity.  Dortet et al. evaluated a 
slightly modified protocol to use this test on positive spiked blood culture samples. 
With this modification the test can be used directly on samples and the detection of 
carbapenemases can be done within 3-5 hours(67). 
4.4.1.6 Chromogenic media 
Many chromogenic media are available for the identification and isolation of 
carbapenem resistane Enterobacteriacae.  Brilliance CRE (Oxoid, Thermofisher 
Scientific, Illkirch, France) CHROMagar KPC (CHROMagar, Paris, France), 
SUPERCARBA medium and chromID OXA-48 (bioMérieux) are some of the 
assessed and used media. 
CHROMagar KPC contains chromogenic media which indicate growth of 
Enterobacteriaceae.  It was useful in detecting high level resistance to carbapenems 
and also was found to have a sensitivity of 40.3% and specificity of 85.5%.  among 
the various classes of carbapenemases it had the lowest sensitivity for OXA-48 
producers of only 13.6% (68).   
Brilliance CRE also contains chromogenic media to differentiate E.coli and other 
Enterobacteriaceae. It was found to have a good sensitivity of 94% but lacked 
specificity 71% as growth  ESBL and AmpC producers was also seen (69).  
Nordmann et al. reported a sensitivity and specificity of 60.7% and 57.1%, 
respectively. The sensitivity to individual Ambler class A,B,C enzymes was found to 
be 85%, 78.4% and 69.8% respectively (68). 
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SUPERCARBA medium is Drigalski agar-based medium to which ertapenem, 
cloxacillin, and zinc sulphate were added to improve detection of low level resistance 
to carbapenems and inhibit growth of non-carbapenemase producers.  The sensitivity 
of detection of carbapenemase produceing organisms by the SUPERCARBA medium 
(96.5%) was greater  
than those of the chromogenic media discussed above. Specificity of the medium was 
60% which lower than CRE Brilliance agar. The sensitivity of this medium for 
detection of Class A and D carbapenemases was found to be 100% (68,70). 
chromID OXA-48 has been found to have a high sensitivity for detection of OXA like 
carbapenemases 91% and also has a higher specificity of 100% as compared to the 
60% of SUPERCARBA (71). 
Chromogenic media chromID® CARBA has also been found to have a sensitivity of 
96.5% and a specificity of 91-100% when used for screening of rectal swabs for 
carbapenemase producing Enterobacteriaceae(72).  
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Table 4.9 Summary of phenotypic tests for detection of carbapenem resistant 
Enterobacteriaceae 
 
 
Phenotypi
c methods 
Carbapen
emases 
Result Comments Refere
nce 
Modified 
Hodge Test 
(MHT) 
KPC, 
OXA-48 
Sensitivity:58% 
Specificity: 93% 
Poorly detects NDM, VIM & 
IMP 
Cannot differentiate class of 
carbapenemase 
False positive results with 
CTX-M ESBL or increase 
amounts of AmpC producers 
Difficult to interpret with 
bacteriocin production 
(73) 
RoscoDiag
nostica 
Neo-
sensitabs 
KPC & 
NDM 
Sensitivity: 80% 
Specificity: 93% 
Poorly detects VIM, IMP & 
OXA -48 
Reliable phenotypic test for 
detection & categorization 
(73) 
RoscoDiag
nostica 
(KPC/MBL 
& OXA-48 
confirm kit 
98015) 
KPC, 
MBL & 
OXA-48 
Sensitivity: 
Class A – 95% 
Class B – 90% 
OXA-48 : 100% 
 
Specificity: 
96% - 100% 
In vitro identification of 
bacteria producing 
carbapenemases and 
oxacillinase by the agar 
tablet/disc diffusion method 
 
Simplistic method of detecting 
bacteria producing KPC, MBL 
and OXA-48. 
 
(74) 
Combined 
disc test or 
disc 
enhanceme
nt test 
Differentia
tes KPC 
from 
NDM 
KPC 
Sensitivity:100
% 
Specificity:98.8
% 
NDM 
Sensitivity 
:100% 
Specificity: 
100% 
Early differentiation of 
carbapenemase 
Good sensitivity & specificity 
(75) 
CHROMag KPC, Sensitivity:40.3 High levels of carbapenem (68) 
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ar KPC IMP, 
VIM, 
NDM, 
OXA-48 
% 
Specificity:85.5
% 
resistance is detected 
Lacks sensitivity 
CRE 
Brilliance 
KPC, 
NDM, 
GIM,VIM, 
OXA -48 
Sensitivity: 94% 
Specificity: 71% 
Often fails to detect OXA -48 
Low specificity 
(69) 
SUPERCA
RBA 
KPC, 
VIM, 
IMP, 
NDM-1, 
OXA-48, 
OXA-181 
Sensitivity:95.6
% 
Specificity:82.2
% 
Detects low level resistance 
Inhibits non-carbapenemase 
producers 
(68) 
chromID 
OXA-48 
OXA-48 
OXA-48 
variants 
with 
carbapene
mase 
properties 
(OXA-
162, 
OXA-181, 
OXA-204 
& OXA-
232) 
Sensitivity : 
91.2% - 96.5% 
Specificity: 
100% 
Lowest limit of detection 
ranges from 1x 10
1 
to 1x 10
2
 
CFU/plate 
chromID OXA-48 is as 
sensitive for detection of OXA-
48 producers as 
SUPERCARBA medium, but 
with higher spwcificity 
(72) 
chromID 
CARBA 
OXA-48 Sensitivity : 
30% 
Specificity : 
67.5% 
Weak sensitivity for detection 
of OXA-48 producers 
Powerful tool for detection of 
all other classes of CPE 
(71) 
Carba NP KPC, 
NMC-A, 
SME, 
GES, IMI, 
NDM, 
VIM, IMP, 
OXA-48 
Sensitivity: 
97.9% 
Specificity: 
100% 
Enzymatic test 
Rapid 
Reproducible 
Inexpensive 
(67) 
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Acinetobacter spp 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ESBL 
production 
screening test 
CPD, CTX DD 
CRO initial screening test 
Ertapenem/meropenem DD 
ESBL 
confirmation 
CTX+CL CD 
test 
CZD+CL CD  
test 
AmpC 
screening 
FOX DD 
AmpC 
confirmation 
ABPA synergy, 
cloxacillin  
ABPA synergy 
+ 
Cloxacillin - 
ESBL 
ABPA 
synergy + 
Cloxacillin + 
DPA synergy High  level of 
MIC for 
Temocillin or 
pipracillin/tazo
bactum 
Class A 
Eg.KPC 
AmpC+ 
Porin loss 
Class B 
 MBL eg. 
NDM 
 
Class D 
Eg. OXA-
48 like 
Modified hodge test/Carba NP test 
Enterobacteriacae  
Carba acineto NP test 
Other mechanisms 
Efflux 
pumps 
Porin loss 
Outer 
membrane 
protein 
detection 
by SDS-
PAGE 
Phenyl arginine  
β-naphthalamine MIC 
+ 
+ 
+ 
+ 
+ 
 
Pseudomonas 
Carba NP test* 
Phenotypic tests for detection of β lactamases  
+ 
* Alternatives: CHROM agar KPC, CRE Brilliance agar, Chrom ID ESBL, ChromID CARBA     
CPD-cefpodoxime, CTX-cefotaxime, CZD- ceftazidime, CL- clavulanic acid, FOX- cefoxitin, DD-disk diffusion, MIC minimum 
inhibitory concentration, ABPA Aminophenyl boronic acid, DPA dipicolinic acid 
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4.4.2 Molecular methods 
 
Molecular methods used for the detection of carbapenem genes are reference tests for 
the identification or the resistance mechanisms. These tests are based on identification 
of the genes encoding the enzymes. Most of the methods are PCR based. The methods 
are rapid and accurate but require costly equipment and trained personnel.  The genes 
that can be detected by these methods are also predefined and new genes may not be 
identified by molecular techniques (76)(13) . 
4.4.2.1 PCR based methods 
 
4.4.2.1.1 Conventional uniplex amd multiplex PCR 
 
PCR is considered a rapid approach to determine the β- lactamase present in a 
suspected carbapenem resistantisolate.  Several uniplex PCR assays targeting a single 
carbapenemase gene type have been used previously. Uniplex PCRs donot prove to be 
cost efficient as the same isolate has to be run for many different genes, a co-existence 
of genes cannot be detected in a single reaction(77).  
Asseveral clinical isolates harbouring more than oneβ-lactamase gene are encountered 
and the enzymes exhibit high varietyand versatility, multiplex PCR techniques are 
being recommended for epidemiological surveys (77).  Ellington et al. in 2007 
established a multiplex PCR assay for the simultaneously detecting five different 
families of carbapenemase encoding genes. IMP, VIM, SPM,SIM and GIM of 
acquired metallo-β- lactamase genes in a single reaction. The multiplex PCR assay 
could reliably detect and differentiatebetween all the genes tested (13)(78). 
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Later, as the other classes of carbapenemases such as the Class A KPC, NDM 
belonging to class B and Class D OXA-48 like enzymes began to emerge an updated 
multiplex PCR protocol was described by Poirel et al. This assay employed three 
multiplex PCR reactions and was aimed at detecting the evolving carbapenemase 
genes KPC, NDM-1 and OXA-48, in addition to the already discovered(79). 
Dallenne et al. designed a multiplex PCR for detection of common β- lactamases in 
gram negative bacilli which caused resistance to third generation cephalosporins and 
carbapenems. The protocol included six multiplex PCR reactions for identification of 
common ESBL, AmpC and Class A,B and D carbapenemase genes (77).  
The multiplex PCR assays had the advantage of detecting the most commonly 
prevalent genes and are less cumbersome than uniplex PCR‟s. 
PCR/electrospray ionization–mass spectrometry (MS) technology is a system which 
has the capacity to detect multiple genes present in an isolate, it also detects single 
nucleotide polymorphisms. This assay has been used to characterize blaKPC enzymes 
in the family Enterobacteriaecae (80). 
 
4.4.2.1.2 LAMP  
LAMP (Loop-mediated isothermal amplification) is an alternative method of DNA 
amplification with high specificity, efficiency and occurs under isothermal conditions. 
It employs a DNA polymerase and a set of four specially designed primers that 
recognise six DNA sequences on the target DNA. The final products of LAMP are 
stem-loop DNAs with several inverted repeats of the target and cauliflower-like 
structures with multiple loops formed by annealing between alternately inverted 
51 
 
repeats of the target in the same strand which enable their simple, easy, selective 
detection by electrophoresis (81). The reaction results in the accumulation of 10
9 
 
copies of target and simply requires a laboratory water bath or heating block to 
maintain a constant temperature of 60–65°C, making it particularly suited to resource 
poor settings. Detection of products is done by agarose gel electrophoresis, real-time 
monitoring in an inexpensive turbidometer or in the form of a colour change when 
SYBR Green I, a fluorescent dsDNA intercalating dye is used which detects turbidity 
or a pellet.  Moreover, the LAMP assay is not affected by polymerase inhibitors (82).  
A LAMP assay for detection of NDM gene using eight primers has been standardized 
and has a sensitivity and specificity comparable to PCR (83).  
 
4.4.2.1.3 Real-time PCR methods 
The first multiplex real-time assay was developed by Mendes et al. to detect MBL 
genes encoding IMP, VIM, GIM,SIM, SPM enzymes. A melt curve step was 
donefollowing the real time PCR and amplicons melting peak analysis was used to 
identify the carbapenemase genes(84). Chen et al. developed a multiples PCR reaction 
which had 100% sensitivity and specificity for detection of blaKPC gene in the ST258 
clone of K. pneumoniae. The assay was a rapid and simple to perform test and 
demonstrated good sensitivity and specificity. It was found to be a useful test for 
ST258 K. pneumoniae surveillance in outbreak and epidemic settings (85).  Recently a 
multiplex real time PCR has been developed for the rapid detection (3 hours) of blaVIM 
,blaKPC , blaGES, blaIMP, blaNDM-1 andblaOXA-48 genes in Enterobacteriaecae.  All the six 
carbapenemase genes looked for in the assay presented a different melting curve after 
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PCR amplification. The assay showed good reproducibility and was rapid for the 
identification of carbapenemase producing clinical isolates (86).   
 
4.4.2.1.4 Microarrays 
Microarray are DNA hybridization techniques that permit simultaneous detection of 
many sequences.Ulyashova et al. established a microarray technique which could 
identify GIM, KPC,OXA, IMP, VIM, SPM and SIM carbapenemases.The technique 
includes a number of steps, comprising DNA extraction from the sample and 
amplification of the gene present a multiplex PCR accompanied by concurrent 
labelling by biotin. The biotin labelled PCR product are hybridized with 
oligonucleotide probes which are immobilized on the surface of a nitrocellulose-based 
DNA microarray. The molecules of biotin thus get attached to the DNA duplexes are 
identified by using streptavidin-horseradish peroxidase as the conjugate. The 
microarray systems which are commercially available for the detection of ESBL‟s and 
carbapenemases have been found to have excellent sensitivity and specificity. 
Microarray technology also proves useful as carbapenemases detection directly from 
blood samples has also been standardized. Sensitivity can be affected by the technique 
used for DNA extraction. Microarrays have not yet been standardized for other 
samples. The major limitation of microarray for routine diagnostics is its high cost and 
requirement of trained technicians. This technique may prove to be of great value for 
epidemiological investigations (13)(87). 
 
 
 
 
53 
 
 
4.4.3 Matrix-assisted laser desorption ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) 
 
The detection of carbapenemase production by the use of MALDI-TOF MS were 
standardized in 2011. In the assay, bacterial culture is mixed withcarbapenem solution 
(meropenem or ertapenem).It is then incubated at 35–37°C for 2–4 h, centrifuged and 
the supernatant is measured by MALDITOFMS. The degradation products and 
carbapenems are assessed for hydrolysis by mass spectrometry. The rate of false 
positivity is low in this technique. Some OXA 48 like enzyme producing strains and 
mucoid strains can give false negative results.  The assay has been standardized for 
Enterobacteriaceae and had a sensitivity of 96.67% and a specificity of 97.87% (88).  
 
4.4.4 Spectrophotometric assays 
For the detection of enzymes by spectrophotometric method a bacterial crude extract 
is prepared and is mixed with a buffered solution of a carbapenem following which 
the hydrolysis of the β- lactam ring is estimated in UV spectra. The limitations of this 
technique is that it is labour intensive but has been proposed as a reference 
confirmatory method for carbapenemase production (89). 
The molecular techniques are summarized in table 4.10 
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Table 4.10 Molecular techniques for identification of carbapenem resistance 
Molecular 
methods 
Carbapene
mase 
Result Comments Referenc
e 
Multiplex 
PCR  
IMP, VIM, 
OXA-48, 
GIM, SPM, 
NDM, 
KPC, GES, 
PER  
Sensitivity:100% 
Specificity:100%       
 
Good sensitivity & 
specificity 
Expensive, requires a 
trained professional.  
 
 
(77,78) 
LAMP 
Assay  
NDM-1  Greater sensitivity 
& specificity than 
PCR  
Rapid, simple, cost –
effective, Specific, 
Gel electrophoresis 
not required 
1pg genomic 
DNA/tube – detection 
limit 
(72) 
Real time 
PCR with 
High 
resolution 
melting 
(HRM) 
KPC Sensitivity:100% 
Specificity :100%       
 
Can differentiate 
between KPC-2 and 
KPC-3 by using HRM 
analysis curve 
 
Rapid and statistical 
differentiation of 
KPC variants 
(85)(90) 
DNA 
microarray 
(Check –
MDR  CT 
102 array)  
NDM, 
VIM, OXA-
48, KPC, 
IMP  
Sensitivity: 97% 
Specificity : 100%  
Practical & Rapid tool 
Expensive  
(91) 
 
Matrix-
assisted 
laser 
desorption 
ionization-
time of 
flight 
(MALDI-
TOFMS)  
VIM, IMP, 
NDM-1 and 
KPC-2 
Sensitivity:96.67
% 
Specificity:97.87
% 
Quick, cheap tool for 
identification 
 
Lowest detection 
limit was found to be 
50µM. 
(88) 
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4.4.5 Detection of non-carbapenemase mechanisms 
The non carbapenemase mediated mechanisms can be over production of ESBL or 
AmpC enzymes with or without porin loss/ overexpression of efflux pumps. 
The loss of porins or occurrence of modified porins can be detected by phenotypic and 
molecular methods. The phenotypic method encompasses extraction of the outer 
membrane proteins by sonication from a pure broth culture followed by 
electrophoresis on polyacrylamide gels with sodium dodecyl sulphate. Bands of 37 to 
40 kDa are encountered with the major porins OmpK35 and OmpK36. The variants 
OmpK36v forms a 35 kDa band and OmpK26 forms a 26 kDa band(93). Molecular 
identification of genes coding for porins and their variants can be done by PCR using 
specific primers(94,95). 
The in vitro tests currently available for detection of efflux pump activity are EPI 
based and non-EPI based methods. The EPI based methods comprise of performing 
the test in two sets, one with the substrate only and the other with both the substrate 
and the EPI. Various substrates used are antimicrobials such as carbapenems or 
fluoroquinolones, fluorescent compounds such as ethidium bromide or bis-benzimide 
and radioactive compounds such as [C
14
] chloramphenicol.  In tests using 
Check-
KPC/ESBL 
microarray 
ESBL 
producers 
(SHV, 
TEM, and 
CTX-M) 
KPC 
Sensitivity & 
specificity -100% 
Novel detection assay 
Potential to detect 
unlimited number of 
genes within one 
reaction 
Rapid and highly 
discriminatory 
(92) 
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antimicrobials, drop in the MIC of the antimicrobial in the presence of EPI denotes 
efflux pump activity(96).Intracellular accumulation of fluorescent or radioactive 
compound when tested along with the EPI signifies the efflux mediated 
resistance(97,98). Non EPI based methods include SDS-PAGE and mass spectrometry 
analysis of bacterial outer-membrane extracts(99). 
 
4.4.6 Strategy for the detection of carbapenem resistance 
 
CLSI and EUCAST have revised their disk diffusion and MIC breakpoints thus 
permitting better recognition of carbapenemase production. However the detection of 
carbapenem resistance based on only phenotypic methods is not sensitive.  CLSI and 
EUCAST recommend the use of special tests for detection of carbapenemase 
mediated mechanism only for hospital infection control and epidemiological 
investigations.  Nordmann et al. disagree with the guidelines and recommend special 
test is suspected isolates as carbapenemase producing bacteria can show in vitro 
susceptibility, but the therapeutic response to carbapenems in such patients is poor 
(89). They also recommend screening for carriers and colonizers to prevent the spread 
of carbapenem resistant bacteria in the hospital environment. (100).The flowchart for 
detection proposed is as follows (fig 4.3) 
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Fig. 4.3 Proposed flowchart for the detection of carbapenem resistant isolates  
 
4.5 Epidemiology of Carbapenemase resistant Enterobacteriaceae: 
4.5.1 Global scenario: 
Resistance to carbapenem group of drugs started to become a problem due to their 
increased use in treating infections caused by ESBL‟s. It has acquired larger 
dimensions in the present world due to spread across continents. Until 1990‟s the 
carbapenemase resistance was a rare entity restricted to sporadic cases in hospitalised 
settings(32). However, data collected over the past decade has suggested a drastic 
Screening of colonized patients Suspected isolate with decreased  
susceptibility to carbapenems 
CarbaNP test 
Molecular characterization for epidemiological purpose 
SUPERCARBA 
medium 
Suspected colonies 
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increase in resistance rates across the world. The initial emergence of carbapenemases 
usually is geographically restricted to a particular country. However, due to the ability 
of intra and inter species transmission of drug resistant plasmids by conjugation leads 
to dissemination across the world. Each of the genes vary in their capability of 
horizontal transfer. KPC, NDM, OXA-48 are the three majorly reported 
carbapenemases belonging to the three classes of ß-lactamases. USA, Israel, Greece 
and Italy are reported to be the key reservoirs of KPC enzymes, NDM are 
predominant in the Indian subcontinent identified in both E.  coli and K. pneumoniae. 
The reservoirs of OXA-48 are both Klebsiella pneumoniae and E. coli identified from 
North Africa and Turkey. Of these enzymes KPC producers arefrequentlyrecognized 
in nosocomial isolates, on the other hand NDM and OXA-48 producers can be 
acquired either nosocomially or from the community (101) The blaNDM-1 gene coding 
for NDM-1 is highly mobile and prefers horizontal spread while the blaKPC gene is 
known for its clonal spread in Klebsiella pneumoniae(32)(102).  ST258 is the 
prodminant clone and its variants ST151 and ST 11 have also been identified(103).  
Individuals from areas where carbapenemases do not exist travel to endemic areas 
seeking medical care. Thus they are susceptible to either infection or colonisation of 
drug resistant organisms. This further leads to spread of these organisms to non-
endemic countries when they travel back.  
4.5.1.1 Class A carbapenemases 
The first documented infection due to a carbapenemase producing organism was in 
1990 in France. This was from an isolate of Enterobacter cloacae  and identified as 
NmcA(32). NmcA belongs to the current Class A (Ambler classification) and is 
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transferred chromosomally across bacteria. However, presently these are not very 
commonly detected(104). Though there were reports which were published later 
following this, the first carbapenemases seems to have emerged in as early as 1982 in 
UK and USA(32).  The enzyme responsible was SME-1 belonged to a patient from 
London. Subsequently SME-2 and SME-3 were identified in various parts of USA but 
remain restricted to sporadic cases(105). Another enzyme belonging to class A is IMI 
which were first detected in 1984 in USA(106). IMI-1 and IMI-2 have been isolated 
from environmental sources across USA(107). The most important among the class A 
enzymes are KPC (Klebsiella pneumoniae carbapenemase). They are predominantly 
plasmid mediated and carry genes conferring resistance to other classes of 
antimicrobials such as Aminoglycosides and fluoroquinolones(32)(6). KPC-1 was first 
isolated from North Carolina in 1996. Currently there are 12 subtypes spread over 
various regions of the world.  Several of these have been identified in various parts of 
USA in tertiary care settings as well as from the community(108). The gene blaKPC is 
carried on a transposon and transmitted across bacteria thus leading to outbreaks in 
hospitalised settings. This has been confirmed by studies done which show a similar 
subtype isolated from almost all samples during an outbreak(109). The gene has also 
been isolated from several European countries and Israel (96). Several studies done in 
the recent past from 2007 onwards in Greece suggest an ongoing epidemic of KPC-2 
in hospitalised patients(108,110). In 2004, KPC was detected in China and then spread 
to South Korea and Taiwan as well. It further spread to Singapore where cases were 
reported in 2012(111). KPC has not only been isolated from isolates of Klebsiella 
pneumoniae but also from other members of Enterobacteriaceae. KPC happens to be 
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the most common carbapenemase across the world (fig4.4)(108). However, due to the 
slow clonal spread of KPC, the rapidly disseminating NDM-1 is expected to become 
the commonest carbapenemase in the coming years(102). 
 
Fig. 4.4 Geographical distribution of KPC producing Enterobacterial isolates 
(Adapted from (101)) 
 
4.5.1.2 Class B carbapenemases:  
Class B metallo-β-lactamases are of two types; chromosomal and plasmid mediated. 
Plasmid mediated genes are mobile and hence are of growing concern due to rapid 
transmission.(fig.4.5)     The first gene identified was IMP-1 from Japan in 1999. 
Later it spread to other European countries, Brazil and other parts of Asia. VIM is 
another enzyme isolated from Italy and now being increasingly identified from 
various parts of the world. Some of the metallo-β-lactamases are geographically 
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restricted such as SPM, GIM, KHM etc(32). Of importance is NDM which kindled 
interest in the world of microbiology for the first time in 2008. The gene was 
identified from a Swedish individual of Indian descent (112). Rapid dissemination of 
this gene across the world has been attributed to its ability to expressed in various 
gram negative bacilli and the mobile nature of the plasmid(32). Several studies 
followed the initial controversy regarding the origin of NDM. It has been suggested 
that NDM might have been circulating in Indian hospitals since 2006(113).  Further 
studies suggested that it might have been imported to India from outside the continent. 
The gene might have been endemic in Balkans according to a studies conducted by 
several groups (114)(115)
 
Fig. 4.5 Geographical distribution of OXA-48-like-producing enterobacterial 
isolates (adapted from (101) 
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4.5.1.3 Class D carbapenemases: 
There are several varieties of class D β- lactamases (oxacillinases) of which only few 
can hydrolyze carbapenems(32). There are around 250 types. OXA -23 was the first 
oxacillinase discovered to have carbapenemase activity. This was isolated from 
Scotland in 1993 from A.  baumaanii Most carbapenem hydrolyzing oxacillinases are 
found in Acinetobacter spp(32)(6). However OXA-48 is found in members of 
Enterobacteriaceae. This was recovered from Turkey for the first time in 2003 from a 
Klebsiella pneumoniae isolate. Initially it was thought to be restricted to the Middle 
Eastern countries. Currently, several outbreaks in various parts of the world have been 
reported. Hospitals across France, Spain, Netherlands, South Africa have reported 
OXA-48 in hospitalized patients(32).The existingdissemination of the blaOXA-48 
gene is most probably associated with the spread of a single  62kbp self-transferrable 
IncL/M-type plasmid which does not transfer any othersupplementary resistance gene. 
OXA-48-type carbapenemases have been recognisedlargely from the Middle 
Eastcountries, North Africa, Turkey and India. These geographical areas constitute the 
most significant reservoirs. However, in the European countriesprevalence of OXA-
48producers has been documented, some of them as hospital outbreaks (11).  Fig.4.6 
shows the geographical distribution of OXA 48 like enzyme producing 
Enterobacteriaceae.  
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Fig. 4.6 Geographical distribution of OXA-48-like-producing enterobacterial 
isolates (Adapted from (11) 
 
 
4.5.2 Indian scenario: 
Data on CRE is being generated in India since the discovery of NDM which raised 
several controversies. Several studies from across the country have estimated the 
prevalence of CRE. Rates vary from 5.3% to as high as 51% (8,116) 
NDM-1 was first identified in early 2008 from a Swedish patient with history of 
hospitalization and treatment in New Delhi, India. Phenotypic and phylogenetic 
studies confirmed the isolate as a novel MBL of Indian origin and hence given the 
name NDM-1. The emergence of this strain generated many political issues.  Indian 
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authorities felt that it would have an unfavourable effect of tourism in India and 
suggested that the name be changed to PCM (Plasmid mediated metallo β- 
lactamase)(117). Several studies followed the initial controversy regarding the origin 
of NDM. It has been suggested that NDM might have been circulating in Indian 
hospitals since 2006(113). Further studies suggested that it might have been imported 
to India from outside the continent. The gene might have been endemic in Balkans 
according to a studies conducted by several groups(114)(115). NDM has gained such 
extensive patterns of spread due to the mobile plasmid. Although initially restricted to 
hospital based infections initially, it spreads to the community in no time due to 
inadequate sanitation facilities. Current data shows that NDM is the most common 
among carbapenemases in India. 
A large surveillance on mechanism of antimicrobial resistance was conducted called 
the SENTRY Antimicrobial Surveillance programme in India. Results of the same 
were published in 2011 which showed that the most common gene isolated was NDM 
(38.4%) followed by OXA-181 (110-117). SMART also showed similar results. The 
other genes found were KPC and VIM(10).  Following table shows results of various 
studies done identify the prevalence of carbapenem resistant Enterobacteriaceae. 
 
 
 
 
 
65 
 
Table 4.11: Epidemiology of Carbapenemase resistant Enterobacteriaceae in 
India 
 
 
 
 
Other than NDM, the genes which have been isolated in India include KPC, VIM, 
OXA. Data regarding OXA-48 is limited, but a few studies suggest the presence in the 
Indian subcontinent. A variant of OXA-48 which is OXA-181 has been reported but 
the magnitude is largely unknown (11). SENTRY study conducted in 2006- 2007 
where samples were collected from major Indian cities such as New Delhi, Pune, 
Region 
where study 
was done 
Total no. of 
Enterobacterial 
isolates 
Prevalence  
of CRE 
Genes identified Ref 
Chennai 
 
3521 4% NDM 31% (118) 
Haryana 198 24% NDM 55% (118) 
Mumbai - 8% NDM 91% (119) 
Jaipur 60 - MBL 88% (120) 
New Delhi 423 51%  (121) 
Guwahati 270 5.1% NDM 100% (122) 
Kanchipur
am 
46 - KPC 67.4 % (123) 
Lucknow 464 12.3% NDM-1 77% 
NDM-5  3% 
NDM-6 14% 
NDM-7  6% 
(124) 
SENTRY 
New Delhi, 
Mumbai, 
Pune 
1443 2.7% NDM-1  57% 
OXA-181 39% 
VIM6 1 isolate 
OXA-181 &VIM6        
1 isolate   
 
(113) 
Pune 
 
300 15% 55.5% OXA 48 and 
NDM coexistence 
 
(9) 
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Mumbai showed that of the carbapenem resistant Enterobacteriacae isolated 57% 
were positive for blaNDM-1,  
39% were positive for blaOXA-181, one isolate showed the presence of VIM6 and 
one isolate showed the coexistence of OXA-181 &VIM6 (113).        
 Only 1.8% of CRE isolates were positive for OXA-48 in a study done in Chennai and 
they concluded that it might not be a major mechanism of resistance(125). In a study 
done in 2014 in central India, the researchers found the co-existence of OXA-181 and 
NDM from an isolate. They also concluded that earlier the detection the better it is to 
limit the dissemination of drug resistant genes (9).  
 
4.9 Treatment options 
Bacteria harbouring the carbapenem resistance genes are extensive drug resistant 
organisms, owing to which limited treatment options are available. These infections 
also lead to frequent therapeutic failures. Colistin and tigecycline are the presently 
available options for treatment of infections due to carbapenem resistant organisms 
(126).  Colistin is available as colistimethate sodium which is the pro-drug 
administered through the intravenous route and has ca concentration dependent 
killing. The pharmacokinetic properties of this drug are variable, it has a poor 
distribution in various body sites. Its side effects include nephrotoxicity and usage of 
colistin leads to quick selection of resistant mutants. The above mentioned factors 
hinder colistin monotherapy(127). 
Tigecycline has a  good in vitro activity against most carbapenem resistant organisms, 
but has variable in vivo activity when used therapeutically. It has a good tissue 
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penetration but a low plasma concentration and hence is not useful in treatment of 
blood stream infections. Breakthrough bacteremia and recurrence of infection are said 
to occur with tigecycline use. Data suggests that patients with severe illness treated 
with tigecycline as a single agent had slightly higher but significant mortality rates 
(128).  
Fosfomycin is a derivative of phosphonic acid, an old antimicrobial agent with 
renewed interest has been evaluated for its efficacy against CRE. It has been observed 
to have a inconstant activity against diverse members of the Enterobacteriaceae 
family. Most strains E. coli, Enterobacter spp. and Citrobacter spp. are susceptible, 
while resistance is noted in over 50% of Klebsiella spp(129). 
Other antimicrobials which can be used for treatment of rarely susceptible strains 
include aztreonam for MBLs without ESBLs, ceftazidime for OXA-48, 
aminoglycosides may be used for non KPC, non NDM-1 producing organisms and 
temocillin for non-carbapenemase mechanisms.(129,130,130) 
Temocillin is a semi synthetic derivative of the drug ticarcillin. Data for its use in 
carbapenem resistant organisms is not available(128). 
Therapeutic use of synergistic combination of antimicrobial agents hasbeen shown to 
have higher success rate than monotherapy with any agent.Studies which compare 
retrospective data favour combination therapy over single agent therapy, as the 
absolute difference in mortality ranges  from20.2% to 46.7%(131). Various 
combinations such as polymyxin B with doxycycline, polymyxin B with rifampicin, , 
tigecycline with polymyxin B and tigecycline-meropenem have been found to act 
synergistically in vitro against CRE(127,130).Colistin-gentamicin combination was 
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reported to be effective in a single study from a patientof endocarditis caused 
carbapenem resistant Klebsiella pneumoniae(132). Although in vitro synergy was not 
observed in fosfomycin-colistin combination, in vivo administration has found to 
lower mortality(133).  In a recent study a combination of three drugstigecycline, 
colistin and meropenem was found to be associated with lower mortality in paitents 
with CRE infections (131). 
Combination of drugs should ideally be tested in vitro for synergy before clinical use. 
Methods for in vitro synergy testing include the time kill assay, the checkerboard 
assay and the E-test methods. Controlled clinical trials are necessary to ascertain the 
optimal combination for therapeutic use(127). 
Interestingly, it has been observed that carbapenems could still be effective in 
treatment of CRE especially in the strains with MICs in the lower range of resistance. 
CRE with carbapenem MICs ≤ 4µg/ml were still found to be susceptible to 
carbapenem both in vitro and in vivo. It is suggested that a high dose or prolonged 
infusion of a carbapenem preferably in combination with another active antimicrobial 
would ensure a favourable outcome. Amikacin, gentamicin and fosfomycin are a few 
antimicrobials which have shown synergy with carbapenems in CRE with low level 
resistance(134). 
 
4.10  Clinical outcome 
 Infections with CRE tend to have adverse clinical outcomes like increased mortality, 
severity and duration of hospital stay.Numerous studies have been conducted 
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comparing the outcomes of CRE versus CSE infection in terms of mortality and in 
almost all studies mortality was found to be higher for CRE infection (Table 5). 
 
 
Table 4.12:Comparative mortality rates of CRE versus CSE 
 
Reference Chang 
et al. (135) 
Ben david et al 
(136) 
Mouloudi et al. 
(137) 
Daikos 
et al. (138) 
Mortality 
Rate (%) 
CRE 94% 48% 56 – 79
*
% 43% 
CSE 50% 17% 41% 16 – 19% 
 
*
  MBLs were associated with lesser mortality than KPC 
  
Various factors are known to influence the outcome of CRE infection independently. 
Microbial eradication and procedures done to remove the focus of infection improves 
recovery and survival.  Borer et al in their study compared the outcome of CRE blood 
stream infections and CRE causing infections and other sites. They found that the 
mortality was higher in CRE bloodstream infections 72% than in other infections 
caused by CRE 22% (139). 
Numerous other factors are also known to contribute to increased mortality in 
bloodstream infections such as advanced age and severity of the underlying disease. 
Astonishingly, Neuner et al inferred from their study that the time to initiate active 
treatment with antimicrobials showing in vitro susceptibility had no significant 
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influence on outcome of the disease. They also established that patients with CRE 
infections had a considerably longer duration of hospital stay. Also the recurrence 
rates of the disease is high, warranting readmission in patients who get discharged due 
to apparent initial improvement(140). 
5. Materials and Methods 
 
5.1 Study Design 
This is an observational study conducted in the Department of Clinical microbiology, 
Christian Medical College and Hospital, Vellore. Samples received from patients for 
blood culture which were positive for screening test for carbapenem resistant K. 
pneumoniae and E.  coli were included in the study. 
 
5.2 Ethics approval 
The approval for the study was obtained from the Institutional Review Board, CMC, 
Vellore.  
 
5.3 Study duration  
The study was conducted over a period of 18 months from January 2013 to June 2014. 
 
5.4 Study samples 
Blood culture was performed on the samples with the BacTAlert automated system 
(bioMe´rieux). Identification of Enterobacteriaceae from positive blood culture was 
done by cultural characteristics and biochemical methods. 
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Antimicrobial susceptibility by disk diffusion was performed as a part of the routine 
testing. 
All isolates showing resistance showing resistance to imipenem /meropenem were 
included in the study to be evaluated for carbapenemase production. 
5.4.1 Inclusion criteria 
i. Any isolate identified as E.  coli or Klebsiella pneumoniae from blood culture 
which was positive for initial screening tests for carbapenem resistance was 
included in the study. 
ii. Multiple blood cultures received from a patient which grew the same isolate, 
only one of the isolates was included. 
iii. For outbreaks, only one strain was included. 
 
5.4.2 Exclusion criteria 
i. Isolates identified as E.  coli or Klebsiella pneumoniae from blood culture 
which was negative for initial screening tests for carbapenem resistance was 
not included in the study. 
ii. Isolates other than E.  coli or Klebsiella pneumoniae were not included. 
iii. Isolates identified as E.  coli or Klebsiella pneumoniae from samples other than 
blood were not included. 
iv. More than one isolate from the same patient was not included. 
 
5.5 Data sources 
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Relevant demographic information about the patient, like age, sex, unit where the 
patient is admitted was obtained from clinical records. Testing of the study samples 
was done in the department of Clinical Microbiology. 
5.6 Study algorithm 
Diagrammatic representation of the study algorithm is shown below. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
Blood cultures positive for gram 
negative bacilli 
Identification of Enterobacteriaceae 
by Culture and Biochemical tests 
CRO initial screening test 
Imipenem, meroprnem DD 
Phenotypic 
CarbaNP test 
Multiplex PCR for blaNDM, blaKPC, 
blaOXA48,blaIMP, blaVIM, genes 
Other 
mechanisms like 
Porins and 
efflux* 
Sequencing for further characterization carbapenemases 
+ 
+ 
+ 
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DD-disk diffusion 
*not characterized in this study   
 
5.7 Processing of study samples 
 
The samples received for blood culture were loaded in theBacT/ALERT
® 
automated 
Blood Culture system. When the bottle fagged positive for growth, a smear was made 
and stained with the Gram‟s stain and the broth was was subcultured onto Blood agar 
and MacConkey agar. 
The gram negative bacilli were identified based on the cultural characteristics and 
preliminary screening media- mannitol motility medium, triple sugar iron agar, indole 
production and citrate utilization. Full characterization of the Klesiella spp and E.  coli 
was done using biochemical tests. 
Antimicrobial susceptibility testing was done by Kirby Bauer disk diffusion technique 
for first and second line antibiotics as per the standard operating protocol (Annexure) 
The isolates found resistant to imipenem and meropenem were included in the study. 
 
5.8 CarbaNP test 
CarbaNP test was performed on all isolates included in the study by the following 
procedure: 
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A. Principle: 
Based on a technique designed to identify the hydrolysis of the β--lactam ring of a 
carbapenem which is indicated by a colour change in the indicator phenol red. 
 
B. Requirements 
 
1. 1.5 ml Eppendorf tubes 
2. Imipenem sodium salt (Sigma-Aldrich)  
3. B-PERII, Bacterial Protein Extraction Reagent (Thermo Scientific, Pierce), 
Cat:78260. 
4. ZnSO4, 7H2O (Sigma-Aldrich, Cat: 221376) 
5. Negative (wild-type E. coli) and positive (K. pneumoniae OXA-48 or K. 
pneumoniae KPC-2) controls. 
 
C. Preparation and storage of Solution A 
1. A concentrated solution of red phenol 0.5% w/v was prepared. 
2. 2 ml of the concentrated red phenol solution (vortexed strongly before 
pipetting to 
resuspend the solution) was mixed in 16.6 ml of distilled water. 
3. The pH was adjusted at 7.8 by adding drops of a NaOH solution (1 N) 
4. 180 μl of ZnSO4 10 mM was added to this to obtain a finalconcentration of 
0.1 mM. 
Solution A is stable at room temperature for 1 week and may be kept at -20°C 
for several 
months. 
Solution A + imipenem (6 mg/ml) was prepared extemporaneously. 
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D. Procedure 
1. 100 μl of 20 mM Tris-HCl lysis buffer (B-PERII, Bacterial Protein Extraction 
Reagent, Thermo Scientific, Pierce) was added in each of two 1.5 ml eppendorf 
tubes 
2.  1/4 to 1/3 calibrated dose (10 μl) of bacterial colonies was resuspended in the 100 
μl of 20 mM Tris-HCl lysis buffer. (Bacterial colonies may be recovered 
directlyfrom the antibiogram around disk of carbapenem performed according to 
the diskdiffusion techniques). 
3. (i) 100 μl of Solution A in the first eppendorf tube and (ii) 100 μl Solution A + 
imipenem 6 mg/ml in the second 1.5 ml eppendorf tube were added. 
4. The tubes were incubated at 37°C for a maximum of 2 hours 
5. Optical reading of the colour of each tube was taken and interpreted as follows: 
 
 
E. Interpretation 
 
Interpretation:No antibiotic      Imipenem        
No carbapenemase                Red                 Red 
Carbapenemase producer      Red                 Orange/Yellow 
Not interpretable                   Yellow            Yellow 
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Fig 5.1: Carba NP test 
 
Usually, the time required for obtaining positive results was as follows: 
1. KPC producers: 2 to 30 min 
2. OXA-48 like producers: 20 min to 1h 
3. Metallo-β--lactamases (NDM, VIM, IMP): 15 min to 1h 
 
5.9 Multiplex PCR 
 
5.9.1 DNA extraction from the isolates 
5.9.1.1 . Materials required 
Suspenstion of isolates in nuclease free PCR grade water (200 µl) 
QIAamp® DNA Mini Kit (Qiagen, Hilden, Germany) containing: 
CarbaNP test positive 
Carbapenemase producer 
CarbaNP test negative 
Carbapenemase non-producer 
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Proteinase K 
Lysis buffer AL 
Wash buffer 1 AW1 
Wash buffer 2 AW2 
Elution buffer AE 
QIAamp Mini Spin Columns 
Collection Tubes (2 ml)  
Ethanol 
Nuclease free water 
Dry bath (temperature to be set at 56°C) 
 
B. Procedure 
DNA extraction was performed in the „PCR dirty‟ room as per manufacturer‟s 
instructions. 
1. Qiagen Proteinase K (20μl) was taken in the bottom of a 1.5 ml microcentrifuge 
tube.  
2. To it 200μl serum sample was added to the microcentrifuge tube.  
3. Then, 200μl Buffer AL (lysis buffer) was added to the sample in the same tube.  
4. These substances were mixed well by pulse vortexing for 15 seconds.  
5. The tube was incubated at 560C for 10 minutes.  
6. After this, the tube was briefly centrifuged to remove the drops from inside the lid.  
7. To the tube, 200μl of absolute alcohol was added to the tube.  
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8. Again, it was mixed well by pulse vortexing for 15 seconds.  
9. Then, the tube was briefly centrifuged to remove the drops from inside the lid.  
10. The mixture was placed in the QIAamp spin column with a 2 ml collection tube 
without wetting the rim and the cap was closed.  
11. The spin column was centrifuged at 8000 rpm for 1 minute.  
12. The QIAamp spin column was placed in a clean 2 ml collection tube and the 
collection tube containing the filtrate was discarded.  
13. The QIAamp spin column was carefully opened and 500μl Buffer AW1 (Wash 
buffer) was added to it without wetting the rim and the cap was closed.  
14. It was centrifuged at 8000 rpm for 1 minute  
15. The QIAamp spin column was placed in a clean 2 ml collection tube and the 
collection tube containing the filtrate was discarded.  
16. The QIAamp spin column was carefully opened and 500μl Buffer AW2 (Wash 
buffer) was added without wetting the rim and the cap was closed.  
17. It was centrifuged at full speed of 14,000 rpm for 3 minutes.  
18. The QIAamp spin column was placed in a clean 1.5 ml microcentrifuge tube and 
the collection tube containing the filtrate was discarded.  
19. The QIAamp spin column was carefully opened and 200μl Buffer AE (eluting 
buffer) was added to it.  
20. The tube was incubated at room temperature for 1 minute.  
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21. It was then centrifuged at 8000 rpm for 1 minute and the spin column was 
discarded.  
22. The 1.5 ml centrifuge tube contained DNA which was labelled and stored at -700C 
in two aliquots. 
 
5.9.2 Detection of genes by multiplex PCR 
Principle: 
Polymerase chain reaction amplifies a specific target region of the template DNA 
strand. This produces DNA fragments of precise lengths giving discreet electrophoretic 
patterns based upon their sizes. Using suitable primers and cycling conditions the five 
gene targets were amplified ina single reaction.  The amplicons were visualized in 
2%agarose gel and were detected depending upon their base pair sizes on 
electrophoresis. 
 
PCR 
A. Primers 
The lyophilised primers used for the multiplex PCR were reconstituted in Tris EDTA 
(TE) buffer and stored in aliquots at -70°C. The primer sequences were as follows:   
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Table 5.1. Primer sequences used for multiplex PCR 
Primer 
name 
Primer sequence(5ˈ-3ˈ) PCR product 
size(bp) 
IMP-F GGAATAGAGTGGCTTAAYTCTC 189 
IMP-R CCAAACYACTASGTTATCT 
VIM-F GATGGTGTTTGGTCGCATA 390 
VIM-R CGAATGCGCAGCACCAG 
OXA-48F TATATTGCATTAAGCAAGGG 800 
OXA-48R CACACAAATACGCGCTAACC 
KPC-F TGTCACTGTATCGCCGTC 1011 
KPC-R CGGGTTGGACTCAAGACG 
NDM-F GGTTTGGCGATCTGGTTTTC 984 
NDM-R CGGAATGGCTCATCACGATC 
 
 
 
B. Preparation of primer mix 
 A primer mix was prepared to dilute the 100µM concentration of the primers to the         
optimal concentration to be used in the multiplex PCR reaction. The primer mix was 
prepared in sterile 1X Tris EDTA buffer as below:   
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C. Master mix preparation 
The concentrations of the different components of the PCR mix for one reaction are 
given below: 
 
Components Required 
amount (µl) 
Final primer 
concentration 
IMP-F  (100 µM) 2 µl 2 µM 
IMP-R (100 µM) 2 µl 2 µM 
VIM-F (100 µM) 2 µl 2 µM 
VIM-R (100 µM) 2 µl 2 µM 
NDM-F  (100 µM) 2 µl 2 µM 
NDM-R (100 µM) 2 µl 2 µM 
OXA-48 F (100 µM) 2 µl 2 µM 
OXA-48 R (100 µM) 2 µl 2 µM 
KPC-F  (100 µM) 2 µl 2 µM 
KPC-R  (100 µM) 2 µl 2 µM 
TE buffer 80 µl  
Total volume of mix 100 µl  
Components Required amount 
(µl) 
Final concentration 
2x multiplex master mix 
(Qiagen) 
10 µl 1x 
5x Q solution 2 µl 0.5x 
10x Primer mix (containing each 
primer at a concentration of 2 
µM) 
2 µl 0.2  µM final concentration 
DNA template 1 µl Not to exceed 0.4  µg 
 dH2O to 20  µl  
Total volume of reaction 20  µl  
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D. Procedure for amplification 
1. The master mix was prepared for the appropriate number of reactions with the above 
template. The master mix was prepared in the clean room or „DNA-free‟ room.  
2. Appropriate number of 0.5ml PCR tubes were labeled appropriately, and the master 
mix was distributed in them. 
3. DNA extracts were removed from the storage area, brought to room temperature 
and spun briefly in a microcentrifuge. 
4. 1 µl of DNA was added and the final volume was 20 µl. Addition of DNA was done 
in the „dirty room‟. 
5. Nuclease free water was used as negative control after every two samples. 
6. Amplification reactions were carried out in Veriti 
TM
 Thermal Cycler (Applied 
Biosystem, Foster City, California, USA) 
7. The cycling conditions were: 
 
Initial denaturation: 95° C 15 min                - 1 cycle 
Denaturation:          94° C 30 sec 
Annealing:              59° C 1.5 min    - 30 cycles 
Extension:               72° C 1.5 min                 
Final extension:      72° C  10 min                 – 1 cycle 
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E. Post amplification DNA detection by Gel Electrophoresis: 
1. Two microliters of each amplicon was mixed with 1 µL of 6X loading dye 
bromophenol blue. 
2. The amplified products were then subjected to electrophoresis in freshly prepared 
2% agarose gel containing 0.5 µg/ml ethidium bromide. 
3. Test samples and negative control were loaded in appropriate wells. Molecular 
ladder (DNA Marker-A, Bio Basic Inc.Canada) used was 100-1000 bp long. 
4. The electrophoresis was done at 100 volts for 75 minutes. 
5. The gel was visualized by ultraviolet radiation using Quantity one® (version 4.6.2) 
software in the gel documentation system (BioRad, Hercules, California, USA). 
6. The positive and negative controls of each run were checked and the run was 
validated. Then the results of the samples were taken 
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Figure 5.2: Documentation under UV light following amplification 
 
 
 
 
 
 
 
 
 
 
 
Lane 1 and 20: 100 to 1000 bp molecular ruler 
Lanes 2-6: Positive controls for blaIMP189bp, blaVIM390bp, bla NDM 984bp, 
blaKPC1011bp, blaOXA48 like800bp bands. 
Lane 8, 13, 14 and 16: Sample positive forbla NDM and blaOXA48 like genes 
Lane 10, 11, 17: Samples positive bla NDMgenes 
Lane 10, 11, 19: Samples positive for blaOXA48 like genes 
Lanes 7, 12, 15, 18: Negative controls 
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5.10 Identification of enzyme variants polymerase chain reaction-sequencing 
A representative set of samples (20 samples positive for blaOXA48 and 7 samples positive 
for blaNDM gene) were bi-directionally sequenced by Sanger sequencing for verification 
of PCR results and to determine the enzyme variants. 
Principle: 
This is a „chain termination‟ method of DNA sequencing to determine the precise order 
of nucleotides in a segment of DNA. After amplification of the target region, the 
products are purified in order to remove extra dNTPs and primers (Pre-cycle sequencing 
clean-up). This is followed by PCR to synthesize single stranded DNA templates. The 
reaction mix for the PCR contains, along with the four deoxynucleotide triphosphate 
(dNTPs), limited amounts of different dideoxy nucleoside triphosphate (ddNTPs).  
These ddNTPs get incorporated into the chain by DNA polymerase, as efficiently as 
dNTPs. However, as they lack the 3'-OH group required for attachment of the next 
nucleotide, their incorporation brings about chain termination. This process generates 
fragments randomly that differ in length by one base pair. In automated cycle 
sequencing using dye terminator chemistry, the ddNTPs are tagged with different 
fluorescent dyes, each emitting light at a unique wavelength when excited by a laser. As 
the products are subjected to capillary electrophoresis in a genetic analyzer, a laser 
excites the fluorescent dye labels at the 3‟ ends of the ddNTPs, and depending upon the 
unique wavelength emitted, the nucleotide is identified as adenine (A), cytosine (C), 
guanine (G) or thymine (T). The emitted fluorescence is recorded by a camera and a 
software converts the data to a colour coded electropherogram, in which blue represents 
C, green represents A, black represents G and red represents T. 
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A. DNA amplification by PCR 
1. Each gene-specific primer mix was prepared in TE buffer and contained 5 M of the 
forward primer and reverse primer.The primers used for sequencing were as follows 
 
 
2. 
The 
ma
ster mix preparation was done in the same manner as PCR reaction above. The cycling 
conditions were also the same.  
3. Amplification of produced a 984bp for base pairs for blaNDM and 800bp for blaOXA48 
like gene. 
4. Electrophoresis of the amplified products was done on 2% agarose gel.  
5. The gel was visualized by ultraviolet radiation using Quantity one® (version 4.6.2) 
software in the gel documentation system (BioRad, Hercules, California, USA). 
 
B. Pre-cycle sequencing clean up  
It was done according to the protocol given by HighPrep PCR (Magbio Genomics, 
Inc. Canada)  
1. The HighPrep PCR reagent was brought to room temperature for at least 30 min 
before use. It was shaken thoroughly to fully resuspend the magnetic beads.  
Gene 
Name of primer Primer sequence 5ˈ-3ˈ 
Product 
size(bp) 
NDM 
preNDMf CACCTCATGTTTGAATTCGCC 
984 bp 
preNDMr CTCTGTCACATCGAAATCGC 
OXA-
48like 
preOXA-48f TATATTGCATTAAGCAAGGG 
800 bp 
preOXA-48r CACACAAATACGCGCTAACC 
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2. To 20μl of PCR amplicon, 36μl of HighPrep PCR reagent was added and mixed 
thoroughly with a pipette 6-8 times in a 1.5 ml eppendorf tube.  
3. It was incubated at room temperature for 5 minutes.  
4. The sample tubes were placed on a magnetic separation device for 3 minutes until 
the solution clears.  
5. With the samples still on the magnetic separation device, the supernatant was 
removed and discarded with a pipette.  
6. Then, 200μl of 70% ethanol was added to each sample tube without removing the 
tubes from the magnetic separation device.  
7. The tube was incubated on the magnetic separation device for 30 seconds at room 
temperature.  
8. The clear supernatant was removed and discarded with a pipette.  
9. Again, 200μl of 70% ethanol was added to each sample tube without removing the 
tubes from the magnetic separation device.  
10. It was incubated on the magnetic separation device for 30 seconds at room 
temperature.  
11. The clear supernatant was removed and discarded with a pipette.  
12. The beads were dried by incubating at room temperature for 5 minutes with the 
plate still on the magnetic separation device.  
13. The samples were removed from the magnetic separation device.  
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14. Finally, 40 μl of water was added to each tube and it was mixed thoroughly five 
times with a pipette.  
15. The samples were placed back on the magnetic separation device and incubated at 
room temperature for 1 minute.  
16. The elute was taken in new 0.5 µl tubes and used for PCR for sequencing and gel 
documentation to detect the product.  
C. PCR for Sequencing  
1. Sequencing reactions were carried out for the forward and reverse strands using 
ABI Prism BigDye® terminator v3.1 cycle sequencing reagents. 
2. The reaction volumes were as follows    
3. The cycling conditions were 
   96°C for 15 seconds 
   50°C for 20 seconds 
   60°C for 4 minutes 
 
 
Reagent Volume per reaction (µl) 
Ready reaction (RR) mix 1 
5 mM MgCl2 3 
Primer (Forward/Reverse) 2 (5µmol/µl) 
Purified PCR product 2 
Nuclease free water 2 
Total volume 10 
25 cycles 
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D. Post cycle sequencing clean-up 
1. 10μl of DTR reagent was taken in a 1.5ml eppendorf tube.  
2. To it 10μl of amplified PCR product and 40μl of 85% ethanol were added and 
mixed well ten times with a pipette.  
3. The tube was incubated for 5 minutes at room temperature on the magnetic 
separation device.  
4. The supernatant was discarded with a pipette.  
5. Then, 100μl of 85% ethanol was added to each tube keeping it on the magnetic 
separation device without mixing.  
6. It was incubated for 2 minutes at room temperature on the magnetic separation 
device and the supernatant was discarded.  
7. Again, 100μl of 85% ethanol was added to each tube keeping it on the magnetic 
separation device without mixing.  
8. It was incubated for 2 minutes at room temperature on the magnetic separation 
device and the supernatant was discarded.  
9. The cap was opened and the beads are allowed to dry by incubating at room 
temperature for 10 minutes.  
10. Finally, 40μl of injection solution was added to it and mixed well.  
11. The tubes were incubated at room temperature for 5 minutes on the magnetic 
separation device.  
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12. The clear supernatant was taken and loaded in the sequencing plate.  
E. Sequencing  
The sequencing plate was loaded in the sequencer to obtain the genomic sequences. 
The ABI 310 Genetic analyser (Applied Biosystems, Foster City, CA, USA) was used 
to enumerate the sequences. 
F. Analysis  
The sequence obtained was visualised and edited using Finch TV (Perkin Elmer, 
Seattle, WA) to attain the final sequence for analysis.  
The homology of the sequence obtained was compared with that of the existing 
blaOXA48 like and blaNDM genesequence in the Gene Bank . This was performed using 
the basic local alignment search tool (BLAST, available from 
www.ncbi.nlm.nih.gov/BLAST) programme with the available standard reference 
sequences in the Gene Bank for homology. 
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Figure 5.3: Sequence analyzed in FinchTV - DNA sequence chromatogram trace viewer for blaOXA48 like gene. 
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Figure 5.4: Sequence analyzed in FinchTV - DNA sequence chromatogram trace viewer for blaNDM gene. 
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6. Results 
 
6.1 Demographic data 
 
During the period of the study from January 2013 to December 2013 over 41,168 
samples were received for blood culture. 
11.1% (n=4585) samples received for blood culture were positive with growth of a 
pathogen.  
44% (n=2031) of the isolates were gram positive cocci 50% (n=2266) were gram 
negative bacilli, 6% (n=270) were Candida spp. And 0.3% (n=18) were Cryptococcus 
spp. (fig6.1) 
 
 
Fig 6.1Distribution of pathogens isolated from blood culture 
Gram positive 
cocci
44%
[CATEGORY NAME]
[PERCENTAGE]
Yeasts
6%
Distribution of pathogens isolated from blood 
culture
94 
 
 
 
The gram negative bacilli included Klebsiella spp, E.  coli, Enterobacter spp, Proteus 
spp., Salmonella Typhi, Salmonelalla Paratyphi A, Non- typhoidal Salmonella, 
Brucella spp, Pseudomonas aeruginosa, Burkholderia pseudomallei and other Non 
fermenting gram negative bacilli (NFGNB). The percentage distribution of these 
isolates are shown in figure 6.2 
 
 
Fig. 6.2 Gram negative bacilli isolated from blood culture 
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A total of 451Klebsiella pneumoniae and 868E.  coli were isolated from January 2013 
to December 2013 which was the duration of the study. 
20% (n=90) of the Klebsiella pneumoniae isolates and 3.6% (n= 32) were positive in 
the screening test for carbapenem resistance.  
After considering the inclusion and exclusion criteria as mentioned in materials and 
methods section, 122 isolates were included in the study. 
All the samples included in the study belonged to the family Enterobacteriaceae and 
were resistant to imipenem, meropenem on screening with disk diffusion technique. 
116 samples were received from hospitalized patients and 6 were received from 
casualty.  
58% (n=71) of the inpatient samples were from the wards and 37% (n=45) were from 
the intensive care units and high dependency units. (fig 6.3) 
 
Fig.6.3 Ward and ICU distribution of patients 
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Majority of the samples were from the hematology unit 33% followed by 23% from 
the various surgical units such as general surgery, hepatobiliary surgery, 
gastrointestinal surgery. 9% of the samples were from the paediatric units and 5% 
were from the oncology units. The remaining samples were from nephrology, 
reproductive medicine, nephrology, neurology, thoracic surgery, orthopaedic surgery, 
cardiovascular surgery and physical medicine and rehabilitation. (Fig.6.4) 
 
 
Fig.6.4 Percentage of samples from different units 
75 isolates (61%) were from males and 47 (39%) were from females (Fig.6.5).  The 
sex distribution was found to be slightly on the higher side for males.  The age of the 
patients ranged from one day old newborns to 84 years. When observed for age 
distribution, maximum number of isolates was from adults between 20 and 60 years 
(Fig.6.6) 
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Fig.6.5: Sex distribution of patients 
 
 
 
Fig.6.6 Age distribution of patients 
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6.2 Microbiological data 
6.2.1 Identification of the pathogens 
 
Of the 122 isolates 74% (n=90) were identified as Klebsiella pneumoniae and 26% 
(n=32) were E.  coli. 
6.2.2 Antimicrobial susceptibility profile 
All the isolates were tested for resistance to carbapenems using imipenem or 
meropenem disk diffusion technique and the zone sizes were interpreted based on 
CLSI 2013 guidelines. The antimicrobial susceptibility profile of the isolates was 
determined for the first line antimicrobial agents by the disk diffusion technique 
(Fig.6.5). All the 122 (100%) isolates were resistant to impenem and meropenem by 
disk diffusion testing.  All the isolates were also resistant to other β- lactam antibiotic 
cefpodoxime and β- lactam/β- lactamase inhibitor combination piperacillin- 
tazobactum, cefoperazone-sulbactum.  6%(n=7) isolates were susceptible to 
gentamicin, 10% (n=12) isolates were susceptible to amikacin and netilmicin. 4% 
(n=5) isolates showed susceptibility to ciprofloxacin.  99% (n=121) of the isolates 
were susceptible to colistin. (Fig. 6.7) 
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Fig. 6.7AST profile of the study isolates for common antimicrobials 
 
6.2.3 CarbaNP test 
 
All isolates were subjected to CarbaNP test to phenotypically differentiate the 
carbapenemase producers and carbapenemase non-producers. The change of colour of 
phenol red indicator to yellow/orange was taken as positive for carbapenemase 
production. Carbapenemase production was noted in 93% (113 out of 122) of the 
isolates with this test. The test was repeated on the negative isolates with an increased 
incubation of the bacterial isolate in the lysis buffer.  On this modification four of the 
negative isolates tested positive thus a total of 96% (117 out of 122) isolates tested 
positive. Five isolates remained negative even on repeat testing. 
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The five isolates which were negative by CarbaNP test, three isolates were Klebsiella 
pneumoniae and two were E. coli.  Among the five negatives, onewas positive for 
blaOXA48 like gene and two were  positive for blaNDM gene by PCR.  Of the CarbaNP 
negative isolates one was also negative by PCR and which was an E. coli isolate. 
6.2.4 Multiplex PCR for blaIMP, blaVIM, blaNDM, blaKPC, blaOXA48 like genes, 
sequencing and BLAST matching. 
A multiplex PCR was done on all the study isolates to detect the presence of 
blaIMP, blaVIM, blaNDM, blaKPC, blaOXA48 like genes. An isolate was considered positive 
for the gene when its amplified products produced the specific band after 
electrophoresis. The position of the band was verified with the 100- 1000bp molecular 
ladder which was run with every set of amplicons. Isolates which did not possess the 
gene did not produce any band. 112 isolates (92%) were found to possess at least one 
of the genes.  
40% (n=49) of the isolates were found to possess the blaNDM gene, 39% (n=48) 
isolates were positive for blaOXA48 like gene. 12% (n=15) of the isolates showed the 
coexistence of both blaOXA48 like and blaNDM genes. None of the isolates were positive 
for blaIMP, blaVIM genes.  8%(n=10) isolates did not show the presence of any of the 
genes. (Table.6.1)  
20 isolates which were positive for the blaOXA48gene and 7 isolates positive for 
blaNDM gene were randomly selected, sequenced, BLAST matched with the reference 
sequences in GenBank. All the 20 (100%) of the blaOXA48 like genes were found to be 
blaOXA181 a variant of the blaOXA48 likegene.  The 7 blaNDM gene positive were found to 
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be blaNDM 1 variant. The sequences showed 100% identity with the reference 
sequences.  
 
Table.6.1 Molecular characterization of the isolates by PCR 
Gene No.of isolates 
(n=122) 
Percentage 
blaNDM 49 41 
blaOXA48 like 48 39 
blaKPC 0 0 
blaNDM 
+blaOXA48 
like 
15 12 
blaVIM 0 0 
blaIMP 0 0 
Negative 10 8 
 
6.3 Characterization of resistance mechanisms: 
 
Among the 122 isolates positive for phenotypic screening test for carbapenem 
resistance by disk diffusion for imipenem and meropenem, 117 were found to be 
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carbapenemase producers by CarbaNP test and 112 were found to possess at least one 
of the five carbapenemase genes. (Table 6.2) 
 
Table. 6.2 Characterization of carbapenem resistance of the study isolates 
 
 
 
 
 
 
 
 
 
 
 
Disk diffusion test CarbaNP test PCR No. of isolates 
+ + + 112 
+ - + 4 
+ + - 9 
+ - - 1 
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7. Discussion 
 
7.1 Carbapenem resistant Enterobacteriaceae 
In this study the organisms Klebsiella pneumoniae and E. coli were chosen to 
represent the family Enterobacteriaceae as they are the most commonly associated 
with acquisition and spread of plasmid mediated carbapenemase genes. Blood stream 
infection is an invasive infection and requires prompt identification of organisms and 
accurate therapy. The K. pneumoniae and E. coli isolates causing blood stream 
infection would truly represent the burden of invasive disease caused by these 
organisms and impact of resistance mechanisms on the outcome of the disease. 
As only K. pneumoniae and E. coli isolates were included in the study the overall rate 
of carbapenem resistance among Enterobacteriaceae considering the other genera 
belonging to this family was about 15% (data not shown/published). This data was 
only derived from the bloodstream isolates. This was at par with those reported from 
other centres in Worldwide and in India. SMART study conducted in 2009, where 
intra-abdominal isolates were screened for carbapenem resistance showed the 
worldwide prevalence of 28% (10).  A multicentric study conducted in various Indian 
cities in 2006-2007 where Enterobacteriaceae isolates were collected from 14 
hospitals, showed an overall prevalence of only 2.7%(113).  The studies published 
more recently suggest that the burden of CRE has steadily risen since then. Dutta et al. 
analysed ten year resistance profile of their blood stream infections and  observed that 
the carbapenem resistance in K.  pneumoniae had risen from 2.4% in the year 2001 to 
an alarming 52% in 2009(121). The differences in the incidence of CRE are due to 
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differences in sites from where the samples have been collected, the usage of 
carbapenem antibiotics for treatment and existence of hospital infection control 
practices. Our hospital is equipped with an active hospital infection control committee 
to prevent nosocomial infections.  The reason for high prevalence of carbapenem 
resistance in a tertiary care center could also be attributed to the fact that patients are 
referred from different hospitals after failure of therapy with multiple antibiotics. The 
possibility of a community acquired CRE infection cannot be ruled out in our country 
as carbapenem resistant Enterobacteriaceae have been found contaminating water 
sources (141). 
Blood stream infection due to E. coli was more common than K. pneumoniae but 
carbapenem resistance was higher in the K. pneumoniae isolates. This was also 
observed in various other studies. In a study by Baroud et al. where the resistance to 
carbapenems was higher in K. pneumoniae 2.45% when compared with E.  coli 1.07%  
(142). 
Majority of the isolates (95%) were obtained from in-patients who have been 
hospitalized either in the wards or intensive care units with only a minor contribution 
from out-patients, which correlates well with the fact that these organisms are 
nosocomial pathogens (10).  Similar results have been seen in studies worldwide.  
Most of these organisms in the studies have been isolated from critically ill  
hospitalized patients who have higher exposure to prior antimicrobial therapy and 
association with indwelling devices (136,137).  
Highest proportion of the in-patients were from the Hematology unit.  The risk of 
developing nosocomial blood stream infections in patients with underlying 
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haematological malignancies is higher, especially in patients who have undergone 
transplantation. The incidence rate was found to be 11-38% in the study by 
Wissplinghoff et al (143).  
In this study the screening test used for identification of carbapenem resistant 
Enterobacteriaceae was disk diffusion testing for imipenem and meropenem. The 
results of the susceptibility testing was interpreted using CLSI 2013 guidelines. CLSI 
revised its carbapenem disk diffusion and MIC breakpoints for Enterobacteriaceae in 
2010, following which it was recommended that with the use of new breakpoints 
modified hodge test for confirmation of carbapenemase production was necessary to 
be done only for hospital infection control and epidemiological purposes.   
 
7.2 Antimicrobial susceptibility profile 
The study isolates were tested for the routinely used first line antimicrobial agents and 
found to be resistant to most of them. This finding of resistance to first line drugs has 
been observed in most of the studies done on CRE around the world. Among the first 
line agents, a small proportion of the isolates were susceptible to gentamicin, 
amikacin, netlmycin and ciprofloxacin.  The susceptibility of CRE to aminoglycosides 
has been reported in many studies. This high susceptibility rate of CRE to 
aminoglycosides is infrequent in Indian studies whereas has been noted in studies 
from the USA and European countries (118)(144)(145). This could due to the fact 
that, the enzyme endemic in Indian subcontinent is NDM. Organisms bearing variants 
of NDM have been found to be inherently resistant to aminoglycosides. On the other 
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hand it is a relatively infrequent feature of the strains producing KPC and other MBLs 
which are more prevalent in the USA and European countries (112)(144)(140).  
Most of the isolates were susceptible to colistin. This finding correlates with many 
studies conducted on CRE around the globe (146)(10). Even though the isolates 
remain susceptible colistin resistanceorganisms have been observed. This drug has to 
be used with caution because colistin monotherapy is associated with selection of 
resistant mutants (127). 
 
7.3 Detection of the different mechanisms of carbapenem resistance 
When tested with the CarbaNP test, 93% of the test isolates tested positive for the 
production of carbapenemase. The sensitivity of this test has been widely evaluated 
and found variable. Dortet et al. and Huang et al. in their study found the sensitivity of 
the CarbaNP test to be 97.9% and 97% respectively (66,67) . On the other hand Tiget 
et al. found the sensitivity to be 76% which was much lower than described earlier. 
The sensitivity was observed to increase to 80% when concentrated bacterial extract 
was used (63).  A similar phenomenon was observed in our study when a concentrated 
bacterial extract was used with prolonged incubation in the lysis buffer, 96% of the 
isolates gave a positive result. As the strains which initially gave a negative test were 
mucoid strains, false positive reactions with mucoid strains used in this test are well 
documented (147).   
Tiget et al also concluded that the CarbaNP test was less sensitive for isolates carrying 
OXA- 48 like enzyme and reported a sensitivity of 55.7% for OXA-48 like producers 
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using the original protocol and 70.9 % using the modified protocol. There are several 
other studies which have established good sensitivity of the test with OXA-48 like 
producers. Dortet et al. have described a sensitivity of 91.3% for OXA-48 like 
producers, and in another study conducted in France in 2012 the sensitivity of 
CarbaNP test for OXA-48 like carbapenemase producers was found to be 100% 
(12,148). In our study out of the five isolates which were negative by the CarbaNP test 
one was positive for blaOXA-48 like gene and three were positive for blaNDM gene. The 
reason for OXA-48 like enzymes showing a positive result in our study could be the 
use of modified protocol that has demonstrated better sensitivity for OXA-48 like 
enzymes. It could also be attributed to the predominant presence of the OXA-181 
variant of the enzyme which has a higher hydrolytic activity towards carbapenems 
when compared to the other enzyme variants in the group(38).The reasons for 
negative result for isolates with blaNDM gene have been the manufacturing of the 
Mueller-Hinton agar used for sub-culturing the isolates. Dortet et al. recommend 
Mueller-Hinton agar plates by Becton Dickinson, as the optimalmedium which has 
optimal concentration of zinc for expression of metallo-β--lactamases (MBL)(148). In 
our study the medium used was the Mueller- Hinton agar by Becton Dickinson, but 
there were three NDM producers which tested negative with CarbaNP. One isolate 
which was negative for the CarbaNP test was also negative for PCR, this could be due 
to the presence of other mechanisms of resistance such as efflux pumps or loss of 
porin channels.  In E.coli and Klebsiella spp. The mechanisms usually observed are 
plasmid encoded AmpC enzymes in combination with loss of porin channels 
OmpK35/36, OmpF or OmpC for E. coli(26).  
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On molecular characterization of these organisms using the multiplex PCR, the 
predominant gene found was the bla NDM gene 40% , which was followed by blaOXA48 
like gene in 39% of the isolates.  Coexistence of blaNDM andblaOXA48 likegenes was 
observed in 12% of the isolates. The high prevalence of NDM was comparable to the 
other studies conducted in the country.  As there is a lack of national surveillance data, 
the prevalence rates can only be compared with the studies published from various 
centres.  SENTRY study conducted in 2006-2007 in various cities in the country 
found the emergence of NDM and OXA-181 enzymes, prevalence being 51% and 
39% respectively(113).SMART study which conducted a worldwide surveillance 
including the Indian subcontinent revealed that majority of the NDM isolates received 
for characterization were from the Indian subcontinent(10). Studies conducted at 
different centres in India also reveal prevalence of NDM from 31% to as high as 90- 
100% (117,118,120–122) 
In our study OXA 48 like enzymes were found common after NDM.  Studies 
conducted in other countries like France and Belgium also reveal OXA-48 and its 
subtypes as the main carbapenemase type (12,66) Data about OXA enzymes from 
India is scarce. A study done by Shanthi et al. on carbapenem resistant isolates from 
different clinical samples showed a prevalence of only 1.8% (125). In contrast to this 
another study by Khajuria et al.from central India on carbapenem resistant 
Enterobacteriaceae from urinary isolates showed co-existence of NDM and OXA in 
55% of the isolates(9).   
KPC production was not observed in any of our study isolates.Nordmann et al. in their 
review stated that though KPC enzymes have been reported from India they are 
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mainly sporadic outbreaks (101). This is in contrast to the study published by 
Shanmugam et al. where they found the prevalence of 67.4%(123).  This variation 
could be due to sites from where the samples were collected and the smaller sample 
size in the study.  The presence of other genes were also not looked for in this study. 
IMP and VIM genes were also not found in any of the isolates in our study. These 
enzymes have been reported as a common cause of carbapenem resistance by Azim et 
al. in the pre NDM era (149). The prevalence of these enzymes has decreased as the 
prevalence of NDM has alarmingly increased in the country. 
Ten isolates did not show the presence of any one of the five genes. This could be due 
to the presence of other carbapenemase genes or non-carbapenemse mediated 
mechanisms(26).  
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8. Limitations of the study 
 
The exact prevalence of carbapenem resistant Enterobacteriaceae in the hospital 
setting was not estimated since the study included only K. pneumoniae andE.  coli 
isolates. The prevalence of carbapenem resistant K. pneumoniae was also not 
calculated because, the study included only the isolates from blood stream infections 
whereas samples from other sources were not included.  Thus the burden of 
carbapenem resistance in invasive infection could only be estimated. 
The identification of other mechanisms or resistance in the PCR negative isolates was 
not performed which could have given insights on rare or novel carbapenemases and 
non carbapenemase mediated mechanism of resistance in these bacteria. 
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9. Conclusion 
 
During the period of study, 122 isolates of carbapenem resistant K.  pneumoniae and 
E. coli were collected from samples received from blood stream infections. Majority 
of the samples were obtained from hospitalized patients (95%), while few isolates 
(5%) were received from casualty which might represent community acquired 
infections also, suggesting the presence of these strains in the community.  
Results of the phenotypic rapid test CarbaNP test advocated that production of 
carbapenemases contributed to the majority of the resistance to carbapenem antibiotics 
(96%). Among the carbapenemases, New Delhi metallo-β-lactamase was the most 
prevalent (40%). This was closely followed by Oxaicillinase OXA-48 like enzyme. 
There was also a coexistence of NDM and OXA-48 like enzymes in 12% of the 
isolates. Enzymes Imipenemase (IMP), Verona integron metallo β- lactamase(VIM) 
and Klebsiella pneumoniae carbapenemase(KPC) were looked for but not found in 
any of the isolates. The OXA-48 like variant in the sequenced isolates was found to be 
OXA-181 and the NDM variant was NDM-1. 
The study isolates were resistant to most of the first line antimicrobial agents.  
Susceptibility to gentamicin, amikacin, netilmicinand ciprofloxacin was noted in a 
minority of the isolates. 99% of the isolates were susceptible to colistin which showed 
good in vitro activity but needs to be use with precaution to prevent emergence of 
resistance. 
The rapid emergence and widespread dissemination of the NDM-1 producing 
Enterobacteriaceaeis now well known. The high prevalence of OXA-181 enzyme in 
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this study could be an indication of the changing epidemiology of the 
carbapenemases. There is also evidence of co-existence of these genes in the 
organisms.  The alarmingly high prevalence of these enzymes poses a definitive threat 
for antimicrobial chemotherapy. There is an urgent need for a rigorous antimicrobial 
policy to prevent emergence of carbapenem resistant strains. Formulating a robust 
hospital infection control policy and implementing it to prevent the spread of CRE is 
the most effective way to control the storm caused by these multidrug resistant 
organisms. 
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Standard operating procedure 
Department of Clinical Microbiology- CMC, Vellore 
 
1. Introduction 
 
It is necessary to perform the antimicrobial susceptibility test as a routine procedure to 
predict treatment outcome with these agents.  
Implications of susceptibility testing results are as follows: 
1. “Susceptible”: High probability of response to treatment with appropriate dosage and 
regimen of the antimicrobial agent 
2. “Resistant”: Treatment with the agent will likely fail or produce no response 
3. “Intermediate”: This may have several meaning 
a. With agent which can be administered at higher dosage, higher dosage can be 
used for response (e.g., β-lactams) 
b. The agent will be effective in infection localised to area where it is 
concentrated in the body (e.g. ciprofloxacin in urine) 
c. For body compartment infection where drug penetration is expected to be poor 
even with inflammation, extreme caution is mandate for the use of the agent 
(e.g. meningitis) 
d. A buffer zone that prevents strains with borderline susceptibility to be 
incorrectly categorised as resistant 
4. “Non-susceptible”: Where resistance is rarely encountered and interpretation is 
available only for the susceptible category 
 
The WHO global report on surveillance for antimicrobial resistance identified lack of 
standards for methodology as one of the key factors for significant gap in surveillance. The 
different sections in this book will describe the various methods used for antimicrobial 
susceptibility testing. For testing susceptibility, the antimicrobial agent contained in a 
reservoir is allowed to diffuse out into the medium and interact in a plate freshly seeded with 
the test organisms. A variety of antimicrobial containing reservoirs are developed but the 
antimicrobial impregnated absorbent paper disk is by far the commonest type used.  The disk 
diffusion method of AST is the most practical method and is still the best method of choice. 
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All techniques involve either diffusion of antimicrobial agent in agar or dilution of antibiotic 
in agar or broth. Even automated techniques are variations of the above methods. 
Antimicrobial susceptibility testing methods are divided into types based on the principle 
applied in each system. They include:  
1. Disk diffusion – Stoke‟s method, Kirby-Bauer method 
2. Dilution method – Broth dilution, agar dilution 
3. Diffusion and dilution – E-test 
2. Requirements for antimicrobial susceptibility testing 
 
In order to derive a meaningful report, appropriate media and quality control strains 
are prerequisites for antimicrobial susceptibility testing. Interpretation of susceptibility testing 
is based on those prescribed by various governing bodies using set standards or guidelines. It 
is important to customise these cut-offs based on the prevailing strains in the particular region 
and the response to therapy at the prescribed dosage regimen. Among the various 
interpretative criteria available, those developed by the Clinical Laboratory Standards 
Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) are commonly used by most laboratories. These guidelines are updated every 
year and it is recommended to follow only the latest guideline based on new evidences.  
 
Media used for susceptibility testing: 
1. should support the growth of the organism 
2. have low thymidine/thymine content which can interfere with testing of drugs acting 
on the folic acid pathway 
3. should have controlled divalent cation levels (Mg2+, Ca2+, Zn2+) which can interfere 
with results of aminoglycosides and tetracycline 
 
  Mueller-Hinton agar (MHA) at pH of 7.2 to 7.4 is recommended for susceptibility 
testing for most non-fastidious organisms as it satisfies all of the above criteria and has less 
batch to batch variations. MHA has also been used and evaluated widely. The media should 
be poured to obtain thickness of 4 mm. Too thick media will give erroneous resistant and too 
thin media will give erroneous susceptible reading.  
 
Other media recommended for fastidious organisms are: 
1. MHA with 5% sheep blood for Streptococcus sp. 
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2. Haemophilus test medium (HTM) for Haemophilus sp. 
3. GC agar with 1% supplements for Neisseria sp. 
 
The appropriate quality control strains (Table 2.1) should be tested in a similar manner to 
the test isolates and should give a result within the expected range for the antimicrobials 
tested weather the zone of inhibition by disk diffusion or MIC. Any result out of range 
indicates an out of control test and appropriate steps should be taken to rectify any cause 
before repeating the test. 
 
Table 2.1: Quality control strains recommendation by CLSI: 
Organism QC strain 
Enterobacteriaceae Escherichia coli ATCC 25922 
Escherichia coli ATCC 35218 for beta-lactam/beta-lactamase 
combination 
Pseudomonas aeruginosa ATCC 27853 for carbapenems 
Pseudomonas aeruginosa Pseudomonas aeruginosa ATCC 27853 
Escherichia coli ATCC 35218 for beta-lactam/beta-lactamase 
combination 
Acinetobacter sp. Pseudomonas aeruginosa ATCC 27853 
Escherichia coli ATCC 35218 for beta-lactam/beta-lactamase 
combination 
Escherichia coli ATCC 25922 for tetracycline and 
trimethoprime-sulfamethoxazole 
Burkholderia cepacia, 
Stenotrophomonas 
maltophilia 
 
Pseudomonas aeruginosa ATCC 27853 
Escherichia coli ATCC 35218 for beta-lactam/beta-lactamase 
combination 
Escherichia coli ATCC 25922 for chloramphenicol, 
minocyclin and trimethoprime-sulfamethoxazole 
Other non-
Enterobacteriaceae 
Pseudomonas aeruginosa ATCC 27853 
Escherichia coli ATCC 35218 for beta-lactam/beta-lactamase 
combination 
Escherichia coli ATCC 25922 for chloramphenicol, 
tetracyclins, sulfonamides and trimethoprime-sulfamethoxazole 
Staphylococcus sp. Staphylococcus aureus ATCC 25923 for disk diffusion 
Staphylococcus aureus ATCC 29213 for MIC 
Enterococcus sp. Staphylococcus aureus ATCC 25923 for disk diffusion 
Enterococcus faecalis ATCC 29212 for dilution methods 
Haemophilius influenzae 
H. parainfluenzae 
Haemophilus influenzae ATCC 49247 
Haemophilus influenzae ATCC 49766 
Escherichia coli ATCC 35218 for testing amoxicillin-
clavulanate 
Neisseria gonorrhoeae  Neisseria gonorrhoeae ATCC49226 
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Neisseria meningitidis  Streptococcus pneumoniae ATCC 49619 
Escherichia coli ATCC 25922 for ciprofloxacin, nalidixic acid, 
minocyclin and sulfisoxazole 
Streptococcus pneumoniae 
and Streptococcus sp. ( β-
haemolyticand Viridans 
group) 
Streptococcus pneumoniae ATCC 49619 
Anaerobes Bacteroides fragilis ATCC 25285 
Bacteroides thetaiotaomicron ATCC 29741 
For Gram positives: Clostridium difficile ATCC 700057 or 
Eubacterium lentum ATCC 43055 
 
 
3. Disk diffusion by Kirby-Bauer method 
 
This method is recommended by the CLSI for routine testing. The accuracy and 
reproducibility of this test is dependent on maintaining a standard set of procedures as 
described here.  
 
3.1 Requirements: 
1. Sterile broth medium in 1.5 ml quantities (nutrient broth / Mueller Hinton broth) 
2. MHA for Non-fastidious organisms. 
3. MHBA for S. pneumoniae and other Streptococci 
4. HTM for Haemophilus spp. 
5. GC agar with 1% growth supplements for Neisseria spp. 
6. Calibrated loop of  2 mm diameter 
7. Antibiotic solution 
8. Sterile filter paper disks / Commercial disks 
9. Pasteur pipettes sterile 
10. Cotton swabs sterile 
11. Normal saline and  / Nutrient broth 
12. McFarland BaSO4 turbidity standard 0.5 
13. Sterile forceps / needle / disk dispenser 
14. 12 x 100 mm sterile test tubes  
15. Measuring scales / sliding calipers  
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16. Table lamp 
17. Zone diameter interpretation charts 
18. Quality control reference strains ( see page no. 4) 
19. Discard jar with disinfectant 
 
3.2 Antimicrobials: 
Antimicrobials for testing may be available as commercial disk of standard size and strength, 
or may be prepared in-house from pure substance. 
 
3.2.1 Commercial disk:  
1. Commercial disk cartridges should be stored at proper temperature according to 
recommendations for the particular agent. Labile agents like imipenem, cefaclor, and 
clavulanic acid combinations should be frozen till day of testing. 
2. Remove the sealed packages or cartridges from freezer one or two hours before test to 
bring it at room temperature. This will prevent condensation forming on the disk. 
3. Check for date of expiry before use and discard all expired disk. 
 
3.2.2 Preparation of antimicrobial solution in-house: 
Preparation of stock solution: 
1. Pure substance of antimicrobial agents may be received as powders or tablets. Do not 
use preparations intended for parentral injections.  
2. Powders must be accurately weighed and dissolved in the appropriate diluents to yield 
the required concentration, using sterile glassware.  
3. Standard strains of stock cultures should be used to evaluate the antibiotic stock 
solution. If satisfactory, the stock can be aliquoted in 5 ml volumes and frozen at -
20ºC or -60ºC. 
4. Prepare antibiotic solution using the following formula: 
 
Weight (mg) = Volume (mL) • Concentration (μg/mL) 
Potency (μg/mg) 
or 
Volume (mL) = Weight (mg) • Potency (μg/mg) 
Concentration (μg/mL)  
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3.3 Preparation of inoculum: 
The inoculum can be prepared by either the growth method or direct suspension method. 
Growth method is usually preferred for non-fastidious organisms and when smooth 
suspension of the organism cannot be made. 
1. With a sterile needle / loop, touch eight or ten well isolated colonies of the same 
morphological type.  
2. Inoculate into 1.5 ml of a sterile suitable broth.  
3. Incubate at 35 – 37oC for   2 – 6 hours to produce a bacterial suspension of moderate 
turbidity. 
4. Adjust the turbidity of the broth to McFarland barium sulphate standard 0.5 with 
sterile saline / broth. This results in a suspension containing approximately 1 to 2 x 
10
8
 CFU/ml for E.coli ATCC 25922.  It should be matched visually in adequate light 
using a card with a white background and contrasting black lines. Else, a photometric 
device can be used. 
 
As a convenient alternative to the growth method, the inoculum can be prepared by 
making a direct broth or saline suspension of isolated colonies and is recommended for 
testing fastidious organisms (Haemophilus spp., N. gonorrhoeae, N. meningitidis, and 
streptococci), and for testing staphylococci for potential methicillin or oxacillin resistance. 
1. Isolated colonies on 18 to 24 hour agar plate from a non-selective medium, such as 
blood agar are suspended in sterile broth or saline. 
2. Adjust to match turbidity of the suspension to 0.5 McFarland standard. 
 
3.4 Inoculation of test plates: 
1. Mark the plates into five sections (100 mm petridish) according to the number of 
antibiotics to be used. 
2. Inoculate the plates within 15 minutes of preparation of suspension so that the density 
does not change. 
3. Dip a sterile cotton swab into the suspension and remove the excess fluid by rotating 
the swab against the side of the tube above the fluid level. 
4. Inoculate the dried surface of a Mueller-Hinton agar plate by streaking the swab over 
the entire sterile agar surface.  This procedure is repeated by streaking two more 
times, rotating the plate approximately 60º each time to ensure an even distribution of 
inoculum.  As a final step, the rim of the agar is swabbed. 
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5. The lid may be left ajar for 3 to 5 minutes, but no more than 15 minutes, to allow for 
any excess surface moisture to be absorbed before applying the drug impregnated 
disks. 
 
3.5 Application of antimicrobial disk: 
1. Dispense the predetermined battery of antimicrobial disks onto the surface of the 
inoculated agar plate within 15 minutes of inoculation of culture.   
2. Each disk must be pressed down to ensure complete contact with the agar surface.  
3. Make sure that they are no closer than 24 mm from centre to centre. Ordinarily, no 
more than 5 disks should be placed on a 100 mm plate. 
4. Because some of the drug diffuses almost instantaneously, a disk should not be 
relocated once it has come into contact with the agar surface.  Instead, place a new 
disk in another location on the agar. 
5. For in-house prepared antimicrobial solution, a 2 mm calibrated loop is used to 
deliver 5µl of the solution into 6 mm disk prepared from Whatmann No.2 filter paper, 
and placed on the surface of the plate. 
6. Incubate the plates in an inverted position in an incubator set to 35±2ºC within 15 
minutes after the disks are applied. 
7. Incubation should be done in ambient air except for Haemophilus sp., N. gonorrhoea, 
N. meningitidis and Streptococcus sp.because the interpretive standards were 
developed by using ambient air incubation, and CO2 significantly alters the size of the 
inhibitory zones of some antibiotics. 
 
3.6 Reading and interpretation of results: 
1. All reading for the test isolate must be taken only when the zone size for the QC 
organism is satisfactory i.e., within the expected zone size range. 
2. Each plates are examined after 16 – 18 hours of incubation. If the test organism is a 
Staphylococcus or Enterococcus spp., 24 hours of incubation are required for 
vancomycin and oxacillin. 
3. If the plate was satisfactorily streaked, and the inoculum was correct, the resulting 
zones of inhibition will be uniformly circular and there will be a confluent lawn of 
growth.  If individual colonies are apparent, the inoculum was too light and the test 
must be repeated.   
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4. The point of abrupt diminution of growth, which in most cases corresponds with the 
point of complete inhibition of growth, is taken as the zone edge. 
5. Measure the diameters of the zones of complete inhibition (as judged by the unaided 
eye), including the diameter of the disk.  
6. Zones are measured to the nearest whole millimeter, using sliding calipers or a ruler, 
which is held on the back of the inverted petri plate, with reflected light.  Zones can 
be measured easily by holding the petri plate a few inches above a black, non-
reflecting background, illuminated with reflected light.   
7. If blood was added to the agar base (as with Streptococci), the zones are measured 
from the upper surface of the agar illuminated with reflected light, with the cover 
removed. 
8. Transmitted light (plate held up to light) is used to examine the oxacillin and 
vancomycin zones for light growth of methicillin or vancomycin- resistant 
Staphylococcus and Enterococcus colonies, respectively, within apparent zones of 
inhibition.  Any discernable growth within zone of inhibition is indicative of 
methicillin or vancomycin resistance. 
 
The zone margin should be taken as the area showing no obvious, visible growth that can 
be detected with the unaided eye.  Faint growth of tiny colonies, which can be detected only 
with a magnifying lens at the edge of the zone of inhibited growth, is ignored.  However, 
discrete colonies growing within a clear zone of inhibition should be subcultured, re-
identified, and retested.   
Strains of Proteus spp. may swarm into areas of inhibited growth around certain 
antimicrobial agents.  With Proteus spp, the thin veil of swarming growth in an otherwise 
obvious zone of inhibition should be ignored.  When using blood-supplemented medium for 
testing Streptococci, the zone of inhibition of growth should be measured and not the zone of 
inhibition of haemolysis.  With trimethoprim and the sulfonamides, antagonists in the 
medium may allow some slight growth; therefore, disregard slight growth (20% or less of the 
lawn of growth), and measure the more obvious margin to determine the zone diameter. 
 
Refer Tables 2A through 2J (Zone Diameter Interpretative Standards and equivalent 
Minimum Inhibitory Concentration Breakpoints) of the CLSI M100-S24: Performance 
Standards for Antimicrobial Susceptibility Testing: Twenty fourth Informational Supplement, 
for interpreting the sizes of the zones of inhibition. Report the organisms as susceptible, 
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intermediate, or resistant to the agents that have been tested. Some agents may only be 
reported as susceptible, since only susceptible breakpoints are given. 
 
If disk diffusion tests are performed with fastidious organisms, the medium, QC 
procedures, and interpretive criteria must be modified to fit each organism. However the 
general rule of testing remains the same. 
 
Table 3.1: Troubleshooting out-of-range QC for disk diffusion: 
 
Observation Probable cause Comments/action 
Many zones too large Too light inoculum 
 
Media depth too 
thin 
 
MHA nutritionally 
unacceptable 
Repeat using McFarland 0.5 
turbidity standard 
Use agar with depth 
approximately 4 mm 
Recheck alternate lots of MHA 
Many zones too small Too heavy inoculum 
 
Media depth too 
thick 
 
MHA nutritionally 
unacceptable 
Repeat using McFarland 0.5 
turbidity standard 
Use agar with depth 
approximately 4 mm 
Recheck alternate lots of MHA 
One or more zones too small or 
too large 
Measurement error 
Transcription error 
 
Random defective 
disk 
Disk not pressed 
firmly against agar 
Recheck readings 
 
 
Retest. If retest results out of 
range and no errors detected, 
initiate corrective action. 
One QC strain is out of range, but 
other QC organisms are in range 
with the same organism 
One QC organism 
may be better 
indicator of a QC 
problem 
Retest the strain to confirm 
reproducibility of acceptable 
results. 
Evaluate with alternative strains 
with known MICs. Initiate 
corrective action with problem 
QC strain/ antimicrobial agents. 
Two QC strains are out of range 
with the same antimicrobial agent 
Indicates problem 
with the disk 
Use alternative lot. 
Check storage conditions and 
package integrity. 
Overlapping zones Too many disk per 
plate 
Place no more than 5 disk per 
plate for 100 mm petridish and no 
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more than 12 disk per plate for 
150 mm petridish.  
Zone too small for 
aminoglycosides, clindamycin, 
macrolides, quinolones 
 
Zone too large for penicillins and 
tetracyclins 
pH of media too low Acceptable pH range is 7.2 – 7.4 
Avoid incubation in CO2 
Zone too small for penicillins and 
tetracyclins  
 
Zone too large for 
aminoglycosides, clindamycin, 
macrolides, quinolones 
pH of media too 
high 
Acceptable pH range is 7.2 – 7.4 
 
Zone for aminoglycosides and 
tetracyclins too small 
Ca
2+
 and/or Mg
2+ 
content too high
 
Use alternative lot of media 
Zone for aminoglycosides and 
tetracyclins too large 
Ca
2+
 and/or Mg
2+ 
content too low
 
Use alternative lot of media 
Zone ≤ 20 mm of E. faecalis 
ATCC 29212 for sulfonamides 
High thymidine 
content 
Use alternative lot of media 
E. coli ATCC 35218 zone too 
small for Amoxicillin-clavulanate 
or Ticarcillin-clavulanate 
Clavulanate is 
labile. Disk potency 
lost. 
Use alternative lot. 
Check storage conditions and 
package integrity. 
Zone initially acceptable but 
slowly decreasing and out of 
range for beta-lactams 
Loss of potency Use alternative lot. 
Check storage conditions and 
package integrity. 
Aztreonam, cefotaxime, 
cefpodoxime, ceftazidime and 
ceftriaxone zone too large for K. 
pneumoniae ATCC 700603 
Spontaneous loss of 
plasmid encoding 
the beta-lactamase 
New culture must be used 
Ampicillin zone too large for 
E.coli ATCC 35218 
Spontaneous loss of 
plasmid encoding 
the beta-lactamase 
New culture must be used 
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